Stockwinners Market Radar for January 04, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:21 EST Cathie Wood's ARK Investment bought 313K shares of SomaLogic today

20:19 EST Cathie Wood's ARK Investment bought 109K shares of Prime Medicine today

20:18 EST Point72 Asset Management reports 5.3% passive stake in Pulmonx - Point72 Asset Management disclosed a 5.3% stake in Pulmonx, which represents over 1.97M shares. The filing does not allow for activism.

20:05 EST GSK, WuXi Biologics enter into license agreement on TCE antibodies - WuXi Biologics (WXIBF) announced a license agreement with GSK plc (GSK) under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms. Under the terms of the agreement, GSK will be granted an exclusive global license for the research, development, manufacturing, and commercialization of a pre-clinical bispecific antibody that crosslinks tumor cells and T cells by targeting a tumor-associated antigen on tumor cells and CD3 expression on T cells and up to three additional pre-clinical TCE antibodies currently at an earlier discovery stage. WuXi Biologics will receive a $40M upfront payment and up to $1.46B in additional payments for research, development, regulatory and commercial milestones across the four TCE antibodies. WuXi Biologics is also eligible to receive tiered royalties on net sales.

19:45 EST Exxon Mobil sees change in Liquids impact Q4 earnings by negative $1.3B-$1.7B - In a regulatory 8-K filing discussing Q4 earnings considerations, the company also sees change in gas prices impact Q4 earnings by negative $2.0B-$2.4B. Reference Link

18:40 EST Occidental Petroleum says winter storm Elliott impacted Q4 output by 10Mboe/d - In a regulatory 8-K filing, the company states: "The late December 2022 North American Winter Storm Elliott resulted in third party and company operated downtime, primarily related to compression, that impacted Occidental's domestic onshore operations. While normal operations have resumed, average Permian and Rockies production in the fourth quarter of 2022 is expected to be impacted by a combined 10 Mboe per day".

17:59 EST Scorpio Tankers announces stock purchases of 415K shares, credit facility - Scorpio Tankers announced that it has purchased its common shares in the open market, the President of the Company, Robert Bugbee, has purchased call options on the common shares of the Company, it has received a commitment for a new credit facility and the Company will participate in at least six investor events during the first quarter of 2023. Recently, the Company purchased 415,062 of its common shares in the open market at an average price of $51.35 per share as part of the Company's securities repurchase program. The President of the Company, Robert Bugbee, has purchased call options on 400,000 common shares The Company has received a commitment from a group of European financial institutions for a credit facility of up to $225M. The credit facility will be used to finance 11 MR product tankers and two LR2 product tankers. The credit facility has a final maturity of five years from the signing date and bears interest at SOFR plus a margin of 1.975% per annum. The terms and conditions, including financial covenants, are similar to those set forth in the Company's existing credit facilities. The credit facility is subject to customary conditions precedent and the execution of definitive documentation, and is expected to close within the first quarter of 2023.

17:50 EST Alpha Healthcare Acquisition Corp III trading resumes

17:18 EST Nutanix chief legal officer Wall sells 90,000 class A shares - In a regulatory filing, Nutanix chief legal officer Tyler Wall disclosed the sale of 90,000 class A common shares of the company on January 3 at a price of $26.1897 per share.

17:12 EST Luminar signed new series production deals for multiple models in December - Luminar announced more commercial momentum at the end of 2022 than anticipated with additional production wins for multiple consumer vehicle models with leading automakers. At CES this week, Luminar will host the North American debut of the Volvo EX90, as well as the SAIC Rising Auto R7, and unveil its new software-based mapping product developed last year following the acquisition of Civil Maps. Luminar will also unveil an updated brand and vision for consumer-facing audiences in preparation for its launch on additional consumer vehicles. "2022 marked an inflection point for Luminar, as the first of its kind to move from R&D to production vehicles," said Austin Russell, Founder and CEO of Luminar...Luminar secured new major commercial program wins for multiple consumer vehicle models with automotive OEMs in the fourth quarter to bring its technology to significantly more cars globally starting in 2025. The commercial success exceeded Luminar's goal of 60% percent year-over-year growth in total program wins and exceeded its target of 60% year-over-year forward-looking orderbook growth, both major milestones for the company in 2022. Luminar acquired Civil Maps, a pioneer and leader in lidar mapping for automotive. Civil Maps provides the foundational technology to build automatically updating high definition 3D maps from production vehicles powered by Luminar... Luminar also continues to advance its holistic Sentinel software stack for consumer vehicles, which is being demonstrated in live drives to attendees throughout CES.

17:03 EST Xerox enters into forward funding agreement with PEAC Solutions - Xerox has entered a Forward Funding Agreement with PEAC Solutions to drive the continued growth of Xerox's FITTLE business. FITTLE is a global provider of equipment leasing and financing solutions for businesses. PEAC Solutions is a portfolio company of the Asset Value Funds sponsored and managed by leading global investment firm HPS Investment Partners. Under the Forward Funding Agreement, FITTLE has the option to sell eligible pools of lease receivables, which PEAC Solutions is committed to purchase on a monthly basis. FITTLE will continue to service the lease receivables for a specified fee and will be paid a commission on lease receivables sold. The Forward Funding Agreement primarily covers U.S. direct originations and has an initial term of one-year, with automatic one-year extensions thereafter, unless terminated by either party. FITTLE expects to sell lease receivables, which would otherwise have been funded by Xerox, totaling approximately $600M during the initial term. Xerox and FITTLE are exploring similar forward funding arrangements for other portions of FITTLE's portfolio of future lease receivables, which are expected to provide incremental growth opportunities for the FITTLE origination platform. Xerox expects proceeds from the Forward Funding Agreement to more than offset a use of free cash flow to fund continued year-over-year growth of FITTLE originations in 2023. Xerox coupled this new funding solution with an opportunity to reduce the commitments under its revolving credit facility by 50% and eliminate its quarter-end minimum liquidity requirement. Accordingly, the amendment to Xerox's credit agreement provides cost savings on the facility, which has never been drawn.

16:56 EST Director of Iridium Rush sells almost $1.5M in company shares - Director of Iridium Parker Rush, disclosed in a regulatory filing that he had sold 27,363 shares of company stock at $54 per share on January 3, for a total transaction amount of $1,477,602.

16:49 EST Riot Blockchain reports December 2022 production and operations - Riot Platforms (RIOT) reported unaudited production and operations updates for December 2022. Riot produced 659 Bitcoins (BTC), up 55% vs. December 2021's 425 BTC. Earned $4.9M in power credits as a result of curtailment activity, equivalent to approximately 290 Bitcoin using the December 2022 weighted average daily closing Bitcoin price of $16,967. Held approximately 6,952 BTC, all produced by self-mining operations, as of December 31, 2022. Sold 600 BTC, generating net proceeds of approximately $10.2M. Had a deployed fleet of 88,556 miners, with a hash rate capacity of 9.7 exahash per second, as of December 31, 2022. During December, Riot received 5,019 new S19-series miners, increased its deployed fleet by 16,128 S19-series miners, with approximately 1,152 miners staged for deployment. Upon deployment of the staged miners, the company expects to have a total of 89,708 miners deployed with a hash rate capacity of approximately 9.9 EH/s. Additionally, shipments of 5,130 S19-series miners have been initiated and are expected to be received during January 2023. During Q1 2023, Riot anticipates a total self-mining hash rate capacity of 12.5 EH/s, assuming full deployment of approximately 115,450 Antminer ASICs, but excluding any potential incremental productivity gains from the company's utilization of 200 MW of immersion-cooling infrastructure. In addition to the Company's self-mining operations, Riot hosts approximately 200 MW of institutional Bitcoin mining clients.

16:31 EST Richardson Electronics jumps 8% to $22.25 after Q2 results

16:29 EST Transocean announces contract awards and extensions totaling $488M - Transocean announced contract awards or extensions for five of its drilling rigs. Together, the fixtures represent approximately $488M of firm backlog. Deepwater Invictus, an ultra-deepwater drillship, was awarded a new three-well contract with an estimated 100-day duration in the U.S. Gulf of Mexico with an independent operator. The contract contributes an estimated $43M in backlog and is expected to commence in direct continuation of the rig's current program.Transocean Barents, a harsh environment semi-submersible, was awarded a new one-well contract with an estimated 110-day duration in the U.K. North Sea with a major operator. The contract contributes an estimated $34M in backlog and is expected to commence in the first quarter of 2023. Additionally, Harbour Energy exercised the third option on its U.K. North Sea contract with Paul B. Loyd, Jr., a harsh environment semi-submersible, for eight P&A wells, adding an estimated $48M in backlog. The additional term is expected to last 275 days and extends the contract to the third quarter of 2024.In Norway, certain previously disclosed options under the Transocean Norge contract with Wintershall DEA and OMV have now been added to backlog. The incremental term is expected to last 773 days and contribute an estimated $331M to backlog. Finally, TotalEnergies exercised a one-well option on its contract with Development Driller III, an ultra-deepwater semi-submersible, working in Suriname. The incremental well is expected to last 90 days and contribute an estimated $32M in backlog.

16:26 EST Inventiva to modify lanifibranor trial after FDA meeting, plans for new trial - Inventiva announced that, following a consultation with the FDA, Inventiva has decided to modify the clinical development plan of lanifibranor for the treatment of NASH. Inventiva's request for a consultation with the FDA followed a public communication by the FDA suggesting that an alternative approach to seek full approval in patients with NASH could be considered upon submission of results of a Phase III trial using a histology surrogate endpoint in patients with NASH and a Phase III clinical outcome trial in patients with NASH and compensated cirrhosis. The company's proposed changes to the NATiV3 trial are designed to align with the alternative regulatory approach and are expected to be beneficial to the overall lanifibranor clinical program by 1) reducing the number of biopsies a patient undergoes during the trial from three to two, 2) reducing the trial duration a patient has to consent to from 7 years to 72 weeks, 3) offering all patients in the trial access to a lanifibranor treatment for at least 48 weeks by allowing them to enter into a new active treatment extension study, and 4) potentially expanding the addressable patient population to include patients with NASH and compensated cirrhosis. The company continues to anticipate submission of a new drug application to the FDA for accelerated approval with such planned submission based on liver histological endpoints of approximately 900 patients treated over a 72-week period. A placebo-controlled exploratory cohort is anticipated to be added in parallel to Part 1 of the NATiV3 trial and will include approximately 200 patients with NASH and fibrosis who are not eligible for Part 1. The Company anticipates that this exploratory cohort may allow the generation of additional results using non-invasive tests and contribute to the safety database requirement to support the planned submission for potential accelerated approval. Under the newly planned trial design, the original Part 2 of the NATiV3 trial, a clinical outcome trial that was previously planned to be conducted in approximately 2,000 patients with F2 and F3 fibrosis for a maximum period of seven years will be replaced by a placebo-controlled Phase III outcome trial which will be event driven and is expected to last approximately three years. The Phase III outcome trial is expected to randomize approximately 800 patients with NASH and compensated cirrhosis. If the results of the outcome trial in patients with NASH and compensated cirrhosis are positive, the company anticipates they will support the submission of an NDA to the FDA for full approval and the potential expansion of the addressable patient population beyond patients with F2 and F3 fibrosis to include patients with NASH and compensated cirrhosis, a patient population at an increased risk of liver-related morbidity and mortality and for which the anti-fibrotic properties of lanifibranor could potentially prevent worsening of the disease. Lanifibranor has been granted both Fast Track and Breakthrough Therapy designations for the treatment of NASH, and the FDA confirmed last year that the Fast Track designation is also applicable to the treatment of NASH for patients with compensated cirrhosis. The Company does not expect these trial design changes to have a significant impact on the funds originally anticipated to be needed to potentially secure accelerated approval in the U.S. or conditional approval in the EU based on the new trial design.

16:20 EST Y-mAbs Therapeutics announces strategic objectives for FY23 - The company said, "Aiming to drive growth for our commercial drug, Danyelza in the U.S. through market growth and potential label expansion to target an estimated U.S. market opportunity of $400M for high-risk neuroblastoma and osteosarcoma alone. Seeking initial validation of the tumor binding capability of our novel SADA platform in solid tumors in the GD2-SADA multicenter trial through the collection of imaging data in patients with small-cell lung cancer, sarcoma, and malignant melanoma. Targeting an IND submission in Q2 2023 for CD38-SADA construct against non-Hodgkin's lymphoma to potentially validate SADA in blood cancers. Seeking partnerships based on the SADA technology platform. Discussing potential regulatory pathway for omburtamab at Type A meeting with the FDA."

16:18 EST Vyant Bio engages LifeSci Capital to explore strategic alternatives - Vyant Bio announced that it has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value. In addition, the Company announced that it is participating in BIO's One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference ."The Company's Board and Management believes that the Company has made tangible progress in its drug discovery strategy focused on the identification of new, disease modifying therapeutics to treat neurodevelopmental and neurodegenerative diseases," said Jay Roberts, Chief Executive Officer of Vyant Bio, "however, the Board and Management also believe that it would be a prudent time to contemplate strategic alternatives while continuing to execute on the current business plan." There can be no assurance that this review process will result in any changes to the Company's current business plans or lead to any specific action or transaction. The Company does not intend to discuss or disclose further developments during this process unless and until its Board of Directors has approved a specific action or the Company otherwise determines that further disclosure is appropriate.

16:15 EST Y-mAbs Therapeutics announces restructuring plan, to reduce workforce by 35% - Y-mAbs Therapeutics announced a strategic restructuring plan designed to extend its cash runway and prioritize resources on the commercialization and potential label extension of Danyelza and development of the SADA technology platform. The company plans to discuss omburtamab at its upcoming Type A meeting with the FDA; however, the company has assumed a deprioritization of the omburtamab program, including all indications, in designing its restructuring plan and in its estimates for 2023. In addition, the company plans to deprioritize other pipeline programs, including activities relating to GD2-GD3 Vaccine and CD33 bispecific antibody constructs, as part of the restructuring plan. The restructuring plan announced is expected to result in a reduction of Y-mAbs workforce by approximately 35% by the end of May 2023. Operating expenses, including restructuring costs which are expected to be recognized in Q1 2023, are expected to decrease by approximately 28% to $115M-120M, compared to previously announced 2022 guidance for operating expenses of $162M-167M. As a result of the estimated decrease in operating expenses, we estimate that our cash and cash equivalents should support our operations as currently planned, taking into account the restructuring plan, into the first quarter of 2026. The total cash burn for the 2023 fiscal year is expected to be in the range of $50M-55m, which is based on an expected 2022 year-end cash position of approximately $106M. Estimated Damyelza net product revenues for the 2023 fiscal year are expected to be between $60-65 million, compared to approximately $47M-48M expected for FY22.

16:13 EST Celularity appoints Paul Graves as Chief Communications Officer - Celularity announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for Celularity as it advances its broad-based clinical pipeline toward U.S. Food and Drug Administration, FDA, submissions and approvals.

16:09 EST SeaSpine, Orthofix complete merger of equals - Orthofix Medical (OFIX) and SeaSpine (SPNE) announced the successful completion of their previously announced merger of equals following the approval of each company's stockholders at respective special meetings of stockholders held today. Of votes cast, 99% of SeaSpine common shares were voted in approval of the merger, and 98% of Orthofix common shares were voted in approval of the merger.

16:08 EST Wearable Devices appoints Tamar Fleisher as COO - Wearable Devices announced that it has expanded its leadership team with the appointment of Tamar Fleisher as Wearable Devices' new Chief Operating Officer.

16:06 EST Resources Connection reports Q2 gross margin up 180bps to 41.1% - Reports Q2 adjusted EBITDA at $29.6M vs. $24.9M y/y.

16:06 EST Forward Air acquires Land Air Express for $56.5M - Forward Air Corporation announced that it has entered into an agreement to acquire the assets of Land Air Express, a privately held full service expedited LTL provider, for $56.5M. The transaction is expected to be funded from both cash on hand and the company's credit facility and is expected to close in January 2023. Land Air Express, headquartered in Bowling Green, Kentucky, offers a variety of services, including guaranteed, standard, exclusive, same day, hot shot and pickup and delivery. With approximately 270 employees and over 200 drivers, Land Air Express operates in over 25 terminals across the United States. Tom Schmitt, Chairman, President and CEO of Forward stated, "Our core LTL business is the key growth area for Forward and the purchase of Land Air Express is an important addition to our LTL growth opportunities. This acquisition will accelerate the expansion of our national terminal footprint, particularly in the middle part of the United States, and we believe it will strategically position us to better meet the current and future needs of customers. Land Air Express is a high-performing team that shares our precision execution DNA and a strong commitment to collaboration with customers. We believe this acquisition will increase our capacity to provide customers with the industry leading on-time and damage-free service they demand. We are thrilled to welcome Land Air Express into the Forward family."

15:41 EST Officer of Maximus David Francis sells over $271K in company shares - Officer of Maximus, David Francis disclosed in a regulatory filing, that he had sold 3,632 shares of company stock at $74.68 per share on January 4, for a total transaction amount of $271,238.

15:14 EST Relativity Acquisition Corp trading halted, volatility trading pause

14:28 EST Auto Lender Credit Acceptance Corp sued by NY AG Letitia James and CFPB - New York Attorney General Letitia James and the Consumer Financial Protection Bureau, CFPB sued Credit Acceptance Corporation, CAC, one of the nation's largest subprime auto lenders, for deceiving thousands of low-income New Yorkers into high-interest car loans. The lawsuit alleges that CAC pushed unaffordable loans onto tens of thousands of low-income consumers throughout the state without considering their ability to repay their loans in full. CAC misstated key terms on loan agreements, including the principal and interest amounts, and did not disclose thousands of dollars in credit charges. In addition, CAC packaged these illegal loans into securities that it sold to investors. These deceptive lending practices lowered consumers' credit scores and cost New Yorkers millions of dollars. The lawsuit seeks to end CAC's abusive and deceptive practices, reform or eliminate existing CAC loan agreements, and collect restitution for impacted consumers. "CAC claimed to help low-income New Yorkers purchase cars, but instead, drove them straight into debt," said Attorney General James. "CAC steered hardworking New Yorkers toward financial ruin by tricking them into unaffordable, high-interest auto loans while cutting backroom deals with dealers to protect their own profits. These predatory actions hurt innocent people and left them with mountains of debt. I thank the CFPB for their partnership to stop this harm and protect everyday New Yorkers." Reference Link

13:53 EST Amazon workers in Coventry announce first UK strike set for January 25 - GMB union, based at Amazon's Coventry warehouse, said in an earlier statement: "Amazon workers in a Coventry warehouse have announced an initial strike date. The first ever Amazon strike in the UK is set to take place on 25 January, with further dates to be announced in the coming weeks. Hundreds of Amazon workers at the fulfilment canter have voted to walk out in anger over the company's 50 pence per hour pay offer. The ballot, which closed on 16 December saw a majority of more than 98 per of workers vote to strike. Amazon UK Services Limited reported that it paid just GBP 10.8M in tax in 2021, despite recording a pre-tax profit of GBP 204M. Amanda Gearing, GMB Senior Organizer, said: "Amazon workers in Coventry are set to make history on 25 January, becoming the first ever Amazon workers in the UK to go on strike." Reference Link

13:32 EST South Atlantic Bancshares names Travis Minter COO - South Atlantic Bancshares, parent of South Atlantic Bank, announced Travis A. Minter has been named chief operating officer for the company."Travis's operational experience and leadership skills will be a key driver in building our product and service offerings to better serve our customers. He has grown and managed our retail banking and mortgage divisions and will now focus on our operational performance to help us gain efficiencies and support our growth," said Scott Plyler, South Atlantic Bank president.

12:45 EST General Motors reports Q4 U.S. sales up 41% to 623,261 units - Earlier, General Motors reported Q4 U.S. sales rose 41% year-over-year to 623,261 units and that its 2022 U.S. sales were up 3% year-over-year to 2,274,088 units. "GM is carrying strong momentum in North America into 2023. We see opportunities to grow our EV market share with nine all-electric models on sale, expand our truck leadership with four new Chevrolet and GMC heavy-duty and midsize pickups, and win new customers with the affordable and stylish 2024 Chevrolet Trax, which is the best entry-level vehicle we've ever built," said Steve Carlisle, GM EVP and President, North America. Among its "2023 Growth Opportunities in EVs," GM lists: Chevrolet Bolt EV and Bolt EUV production expected to increase to more than 70,000 units this year to meet strong global demand; Three Chevrolet EVs launching in the industry's most popular segments; Cadillac LYRIQ production continues to increase to meet strong customer demand; GM's first Ultium-dedicated assembly plant - Factory ZERO in Detroit and Hamtramck - slated to resume production this month with GMC HUMMER EV SUV planned to launch mid-2023. Reference Link

12:25 EST Model Performance Acquisition Corp trading resumes

12:03 EST Rekor Systems announces multiple State DOT task orders, contract extensions - Rekor Systems announced that the Pennsylvania Department of Transportation, Florida Department of Transportation, Mississippi Department of Transportation, Alabama Department of Transportation and the Ohio Department of Transportation have issued new or extended existing contracts and task orders with the Company that will feature the use of the Company's advanced non-intrusive technology. The collective total contract value is expected to be over $5M. The Company also announced that its AI vehicle recognition technology is now deployed in New York state as a part of a roadway non-intrusive proof of capability study to support the federally required vehicle classification process with the New York State Department of Transportation. A similar study is also being conducted with the South Carolina Department of Transportation.

12:00 EST Pimco California Municipal Income Fund falls -13.7% - Pimco California Municipal Income Fund is down -13.7%, or -$2.10 to $13.21.

12:00 EST Dingdong rises 18.6% - Dingdong is up 18.6%, or 82c to $5.24.

12:00 EST Silvergate Capital rises 23.0% - Silvergate Capital is up 23.0%, or $3.97 to $21.24.

11:56 EST BP increases investment in onshore U.S. oil and gas to $2.4B in 2023 - BP America said that it is increasing investment in onshore U.S. oil and gas business, mostly in Texas, from $1.7B in 2022 to $2.4B in 2023. The company also intends to raise its Gulf of Mexico investment to an average of $2.3B a year in 2023 to 2025 from $2B per year in the past five years. Dave Lawler, chairman and president of BP America, wrote, "We are proud of our 150-year history in the United States, and we're committed to America for the long term as we transform our company in line with our ambition to reach net zero emissions by 2050 or sooner, and help the world get there too."

11:49 EST Nissan reports Q4 U.S. sales down 2% to 191,012 units - Nissan Group announced total U.S. fourth quarter sales for 2022 of 191,012 units, a decrease of 2.0% versus the prior year. Nissan Group also announced total calendar year 2022 U.S. sales of 729,350 units, a decrease of 25.4% percent compared to the prior year.

11:32 EST Stellantis to build electric aircraft with Archer Aviation - Stellantis (STLA) and Archer Aviation (ACHR) announced that they have agreed to significantly expand their partnership by joining forces to manufacture Archer's flagship electric vertical take-off and landing aircraft, Midnight. Stellantis will work with Archer to stand up Archer's recently announced manufacturing facility in Covington, Georgia at which the companies plan to begin manufacturing the Midnight aircraft in 2024. Midnight is designed to be safe, sustainable, quiet and, with its expected payload of over 1,000 pounds, can carry four passengers plus a pilot. With a range of 100 miles, Midnight is optimized for back-to-back short distance trips of around 20 miles, with a charging time of approximately 10 minutes in-between. The goal is for Stellantis to mass produce Archer's eVTOL aircraft as its exclusive contract manufacturer. As a further sign of its commitment, Stellantis will provide up to $150M in equity capital for potential draw by Archer at its discretion in 2023 and 2024, subject to achievement of certain business milestones which Archer expects to occur in 2023. Stellantis also intends to increase its strategic shareholding through future purchases of Archer stock in the open market. These actions, along with the other elements of this expanded partnership, will enable Stellantis to become a long-term, cornerstone investor in Archer.

10:39 EST Mazda North America reports December sales up 40.5% to 27,292 vehicles - Mazda North American Operations reported total December sales of 27,292 vehicles, an increase of 40.5% compared to December 2021. With 27 selling days in December, compared to the same the year prior, the company posted an increase of 40.5% on a Daily Selling Rate, or DSR, basis.

10:32 EST Patterson-UTI sees Q4 net income exceeding $100M, adjusted EBITDA over $230M - Patterson-UTI said earlier that it expects its net income for the fourth quarter of 2022 to exceed $100M and its adjusted EBITDA for the fourth quarter of 2022 to surpass $230M, based on current projections. In aggregate, the company returned $74.3M to shareholders in the fourth quarter through its regularly scheduled dividend and the purchase of approximately 3.3 million shares of its common stock for $57.2M. The company also repurchased $22.4M of its long-term indebtedness during the fourth quarter. "In contract drilling, average rig revenue per day benefited primarily from contract renewals with more favorable pricing than expected," stated Andy Hendricks, Patterson-UTI's CEO.

10:18 EST Toyota Motor North America reports year-end 2022 U.S. sales 2,108,458 vehicles - Toyota Motor North America reported year-end 2022 U.S. sales of 2,108,458 vehicles, a decrease of 9.6 percent on a volume basis and a decrease of 9.9 percent on a daily selling rate basis compared to 2021. The company reported U.S. fourth quarter 2022 sales of 536,740 vehicles, an increase of 13.1 percent on a volume basis and DSR basis compared to the fourth quarter of 2021. U.S. December 2022 sales totaled 180,147 vehicles, an increase of 3.5 percent on a volume basis and DSR basis compared to December 2021. "In 2022, we further solidified our leadership position in electrified vehicles, and through our 20 electrified options, we're giving customers a choice that fits their lifestyle and needs," said Jack Hollis, executive vice president, Sales, TMNA.

10:09 EST Irish Data Protection Commission reports conclusion of inquiries into Meta - The Data Protection Commission has announced the conclusion of two inquiries into the data processing operations of Meta Platforms Ireland Limited in connection with the delivery of its Facebook and Instagram services. Final decisions have now been made by the DPC in which it has fined Meta Ireland EUR 210 million for breaches of the GDPR relating to its Facebook service, and EUR 180 million for breaches in relation to its Instagram service. Meta Ireland has also been directed to bring its data processing operations into compliance within a period of 3 months. The inquiries concerned two complaints about the Facebook and Instagram services, each one raising the same basic issues. One complaint was made by an Austrian data subject in relation to Facebook; the other was made by a Belgian data subject in relation to Instagram. Notably, it found that: In breach of its obligations in relation to transparency, information in relation to the legal basis relied on by Meta Ireland was not clearly outlined to users, with the result that users had insufficient clarity as to what processing operations were being carried out on their personal data. In circumstances where it found that Meta Ireland did not, in fact, rely on users' consent as providing a lawful basis for its processing of their personal data, the "forced consent" aspect of the complaints could not be sustained. Reference Link

10:09 EST Meta to appeal both 'substance' of Irish DPC rulings and fines - Meta noted that the Irish Data Protection Commission, or DPC, has set out its findings on the legal basis that Facebook and Instagram use under GDPR for the purpose of serving behavioral advertisements. In a post to its site in reply, Meta stated: "The debate around legal bases has been ongoing for some time and businesses have faced a lack of regulatory certainty in this area. We strongly believe our approach respects GDPR, and we're therefore disappointed by these decisions and intend to appeal both the substance of the rulings and the fines. There has also been inaccurate speculation and misreporting on what these decisions mean. We want to reassure users and businesses that they can continue to benefit from personalised advertising across the EU through Meta's platforms." Reference Link

10:06 EST Sight Sciences, Verana Health collaborate on glaucoma research - Verana Health and Sight Sciences announced a research collaboration designed to provide insights that may lead to improved outcomes for patients with primary open-angle glaucoma. Sight Sciences will leverage Verana Health's Qdata Glaucoma RWD module to evaluate various facets of its OMNI Surgical System - a minimally invasive, implant-free glaucoma procedure that uniquely addresses all three known points of resistance in the aqueous outflow system: the trabecular meshwork, Schlemm's canal and the collector channels. Intraocular Pressure is the only known modifiable risk factor for glaucoma, and OMNI enables surgeons to reduce IOP while avoiding more aggressive surgical interventions or foreign body implants associated with legacy minimally invasive glaucoma surgery procedures. OMNI is indicated for canaloplasty followed by trabeculotomy, and can be used before, in combination with, or following cataract surgery.

10:05 EST Cinedigm signs exclusive agreement with Cirque du Soleil - Cinedigm signed an exclusive agreement with Cirque du Soleil to bring nearly 30 hours of live show performances, documentaries, and acrobatic content to AVOD, FAST and TVOD platforms across the US. Beginning March 2023, Cinedigm will feature blocks of Cirque du Soleil content on its flagship streaming service Cineverse along with Dove Channel, Docurama, and AsianCrush, in addition to releasing select content to its third-party platform partners. Cirque du Soleil plans on expanding its content offering by adding new series and show-based programs throughout 2023.

10:03 EST Dalan Animal Health granted USDA conditional license for honeybee vaccine - Dalan Animal Health announced that the U.S. Department of Agriculture granted a conditional license for vaccination of honeybees against American Foulbrood disease caused by Paenibacillus larvae.The bacterin was developed by Dalan Animal Health, and is manufactured by Diamond Animal Health, a wholly-owned subsidiary of Heska.

10:00 EST Pimco California Municipal Income Fund falls -12.7% - Pimco California Municipal Income Fund is down -12.7%, or -$1.94 to $13.38.

10:00 EST Biohaven rises 9.0% - Biohaven is up 9.0%, or $1.22 to $14.72.

10:00 EST Amwell rises 10.3% - Amwell is up 10.3%, or 29c to $3.11.

09:54 EST ATX Group, Inc. announces entry into securities purchase agreement - Addentax Group Corp. announced that it has entered into a securities purchase agreement with certain accredited investors for the sale and issuance of a new series of senior secured convertible notes in the original principal amount of $16,666,666.66 and common stock purchase warrants purchase up to 16,077,172 shares of common stock of the company at an exercise price of $1.25 per share, subject to customary closing conditions. The net proceeds, after original issue discount will total $15M. The company expects to use the proceeds from the sale of the Notes for general corporate purposes, which may include, among other things, research and development, legal and accounting fees. Univest Securities, LLC served as the sole placement agent in the transaction.

09:49 EST NY DFS announces $100M settlement with Coinbase - Superintendent of Financial Services Adrienne A. Harris announced that Coinbase, Inc. will pay a $50M penalty to New York State for significant failures in its compliance program that violated the New York Banking Law and the New York State Department of Financial Services' virtual currency, money transmitter, transaction monitoring, and cybersecurity regulations. These failures made the Coinbase platform vulnerable to serious criminal conduct, including, among other things, examples of fraud, possible money laundering, suspected child sexual abuse material-related activity, and potential narcotics trafficking. In addition to the penalty, Coinbase has agreed to invest an additional $50M in its compliance function over the next two years to remediate the issues and to enhance its compliance program pursuant to a plan approved by DFS. "It is critical that all financial institutions safeguard their systems from bad actors, and the Department's expectations with respect to consumer protection, cybersecurity, and anti-money laundering programs are just as stringent for cryptocurrency companies as they are for traditional financial services institutions," said Superintendent Harris. "Coinbase failed to build and maintain a functional compliance program that could keep pace with its growth. That failure exposed the Coinbase platform to potential criminal activity requiring the Department to take immediate action including the installation of an Independent Monitor." Reference Link

09:47 EST Pimco California Municipal Income Fund falls -12.5% - Pimco California Municipal Income Fund is down -12.5%, or -$1.92 to $13.40.

09:47 EST Scor ADR rises 6.7% - Scor ADR is up 6.7%, or $1.70 to $27.14.

09:47 EST Hayward rises 9.6% - Hayward is up 9.6%, or 95c to $10.89.

09:36 EST Salesforce up 4% to $139.85 after announcing restructuring - Salesforce shares are up 4% in to $139.85 in early trading after announcing a restructuring that will include a 10% workforce reduction.

09:31 EST Scilex Holding Co trading halted, volatility trading pause

09:23 EST Terreno Realty acquires industrial property in California for $22.4M - Terreno Realty acquired an industrial property in Rancho Dominguez, California on December 30 for a purchase price of approximately $22.4M.

09:19 EST Roivant Sciences up 9% in pre-market at $7.78 after RVT-3101 phase 2b study data

09:18 EST California Resources announces CDMA for CTV's carbon storage project - California Resources announced a Carbon Dioxide Management Agreement, CDMA, between Carbon TerraVault Holdings, CTV and Grannus, an independent clean-tech company that is building a portfolio of blue ammonia and hydrogen production facilities to supply the agriculture, mobility and marine fuel markets, to sequester 370,000 metric tons of carbon dioxide per annum at CTV III from a new blue ammonia and hydrogen plant to be constructed in Northern California. Called the Grannus Blue Ammonia and Hydrogen Project, the project aims to be California's first blue ammonia and hydrogen facility producing 150,000 MT per annum of blue ammonia and 10,000 MT per annum of blue hydrogen. The blue ammonia facility will use Grannus' patented process which is expected to operate a virtually emissions-free facility once the CO2 is sequestered. The facility will produce blue hydrogen which is combined with nitrogen to produce ammonia for use in nitrogen-based fertilizers, while the generated CO2 will be captured and then stored permanently underground by CTV. California produces over a third of the country's vegetables and three-quarters of the country's fruits and nuts, providing a strong ammonia market in the state. The blue ammonia fertilizer is expected to be supplied to CALAMCO, an investor in Grannus and a California-based cooperative made up of approximately 900 dealer and grower members, which represents the majority of agricultural ammonia demand in the state.

09:12 EST Orion, Amneal enter long-term license agreement for generic products - Orion (ORINY) receives exclusive licence to commercialise Amneal's (AMRX) generic products in Europe, Australia and New Zealand. Orion announced it has signed a long-term license agreement with Amneal Pharmaceuticals, Inc. to commercialise Amneal's generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialise and sell Amneal's generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include a mix of generic products commercially available in the U.S. today, as well as selected pipeline products currently under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years. Orion and Amneal will work together to develop and register products to Orion markets.

09:10 EST Stran & Company CEO delivers 2022 review to shareholders - Stran & Company provided the following business update from the Company's CEO, Andy Shape. "As we enter 2023 and conclude a very busy and growth-oriented 2022, I'd like to take time to reflect on our achievements and plans moving into the new year. During the year, we achieved a number of important milestones that we believe further solidified our foundation for ongoing success in the $23 billion promotional products industry. Specifically, we secured several meaningful multi-year contracts, completed complementary acquisitions, expanded our experienced executive team, advanced our technology offerings, and launched initiatives to further accelerate growth-culminating in 50% year-over-year revenue growth for the nine months ended 2022 compared to the same period in 2021. We started 2022 by securing a multi-year contract with a large national healthcare company. This contract demonstrated our ability to shape consumer behavior by providing incentive products and literature to consumers, which, in turn may allow us to expand our business within the healthcare industry... More recently, we secured a significant contract with a leading North American infrastructure services company to provide promotional products and services. We were selected by this company due to our solid reputation in the industry and ability to provide exceptional products, while assisting them in reaching their goal of increasing their market awareness and customer loyalty. I'd like to note that this contract came as a referral from an existing customer, which we believe validates our ability to execute... In addition to the contracts mentioned above, we also expanded our customer-facing technology offerings by launching more than 35 online stores for various customers throughout the year. ... On the M&A front, we continue to execute on our strategy and have completed meaningful and complementary acquisitions. In February, we completed the acquisition of G.A.P. Promotions... Specifically, with GAP Promo, we improved our capabilities within the beverage market and added an impressive roster of top-tier beverage and consumer packaged good clients to our portfolio... And lastly, in December, we successfully completed our third acquisition of 2022 with Premier Business Services.. With over 30 years of experience in the promotional products industry, Premier NYC has developed a number of long-term client relationships with large law firms and other elite customers, which we intend to leverage by enhancing their solutions through implementation of our proven technologies.Looking ahead, we strive to be a leader in the promotional products industry and intend to do this by promoting brand awareness and affecting behavior through visual, creative and technology solutions."

09:09 EST Know Labs gets new foundational glucose monitoring patent - Know Labs announced it has been granted a new foundational patent that equates the company's Bio-RFIDTM diagnostic technology to a current reference standard for glucose monitoring, widely used by diabetes researchers, hospital labs and glucose meter manufacturers, and establishes a specific, superior benchmark range of clinical accuracy, known as the MARD or Mean Absolute Relative Difference. The new patent extends the Know Labs IP portfolio to nearly 90 patents issued and pending, reinforcing the company's position as the top worldwide IP holder in non-invasive blood glucose monitoring. "Intellectual property development is a critical pillar of our success," said Ron Erickson, Know Labs Founder and Chairman. "We make significant investments in the strategic development of our IP Portfolio, which creates long-term value for our shareholders, improves our competitive position and accelerates our efforts to bring the first FDA-cleared, truly non-invasive glucose monitoring device to the market."

09:07 EST Pulmatrix announces 'positive' data from Phase 1 study of PUR3100 - Pulmatrix announced successful completion of a Phase 1 trial evaluating safety and pharmacokinetics of PUR3100 in healthy volunteers. PUR3100 uses the company's iSPERSE formulation technology to create an orally inhaled dry powder formulation of dihydroergotamine for the treatment of acute migraine. The Phase 1 trial, performed at Nucleus Network in Melbourne, Australia, was a double-dummy, double-blinded design to assesses the safety, tolerability, and pharmacokinetics of three dose groups of inhaled PUR3100 with intravenous placebo, compared to a single dose of IV DHE with inhaled placebo. Twenty-six healthy subjects were enrolled and each of the four groups contained at least six subjects. PUR3100 was well-tolerated and there was a lower incidence of nausea in PUR3100 dose groups compared to IV DHE. No emesis was observed in any of the PUR3100 dose groups. Oral inhalation of PUR3100 achieved peak exposures in the targeted therapeutic range at all doses and the Tmax occurred at 5 minutes after dosing. Pulmatrix plans to present the data at an appropriate upcoming scientific conference. Dose selection is underway for the Phase 2 study and an FDA meeting will be requested this month.

09:06 EST HeartSciences appoints Wells to its board of directors - Heart Test Laboratories announced it has appointed David Wells to its Board of Directors, effective December 28, 2022. Patrick Kanouff has contemporaneously resigned from the Board of Directors. Wells brings over 30 years of senior financial management experience. Most recently, he founded Atlas Bookkeeping, LLC, a technology-based financial services firm that provides bookkeeping and reporting services for emerging growth and small cap public and privately held companies.

09:05 EST Dominari Holdings provides update on share repurchase program - Dominari Holdings provided an update on the $2M share repurchase program authorized by the company's Board of Directors on December 5, 2022. The company reported that on January 3, 2023, the company purchased 4,900 shares of common stock at $3.3996 per share. Anthony Hayes, CEO of Dominari, stated, "We believe the company's stock price is still trading significantly below value and continuing to repurchase shares in the open market is a prudent allocation of our capital."

09:04 EST Biomea Fusion announces dosing of first patient in COVALENT-111 study - Biomea Fusion announced dosing of the first patient with type 2 diabetes in the Phase II portion of COVALENT-111 in the U.S. This trial is a randomized, double-blinded, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of six dose levels of BMF-219 administered orally daily in 28-day cycles followed by a 26-week evaluation period. "We are thrilled to announce this milestone so soon after receiving IND clearance from the FDA in December. BMF-219 is potentially capable of addressing and modifying a major driver of type 2 diabetes, beta cell health and function. We believe that this oral agent has the potential to obviate the need for multiple concurrent treatments, including insulin injections," stated Thomas Butler, Biomea Fusion's Chief Executive Officer, and Chairman of the Board. "We look forward to presenting initial data from the Phase II portion of COVALENT-111 later this year as we march toward our goal of delivering a transformational therapy for patients with diabetes."

09:04 EST Hyundai Motor America reports December total sales of 72,058 units, up 40% y/y - Hyundai Motor America reported total December sales of 72,058 units, a 40% increase compared with December 2021 and the highest December sales in Hyundai history. Retail sales were up 27% in December, marking the fifth consecutive month of record-setting retail sales. SUVs were 74% of retail sales with more than 47,800 units sold. December saw the best-ever retail and total sales for Venue, Elantra HEV, Elantra N, IONIQ 5, Santa Fe HEV, Tucson HEV, Santa Cruz, Kona EV and Kona N. Eco-friendly vehicle retail sales grew 72% compared with December 2021.

09:03 EST Inhibrx, NorthStar Medical Radioisotopes enter collaboration to treat cancer - NorthStar Medical Radioisotopes and Inhibrx announced a collaboration to develop and produce novel radiopharmaceuticals for the treatment of cancer. Inhibrx will use its optimized single-domain antibodies to create a new generation of targeted alpha therapies. Inhibrx has an extensive history of sdAb innovation and has developed a library of sdAbs targeting tumor-associated antigens. sdAbs are ideal biological targeting agents for delivery of radioisotopes, due to their high binding affinity and specificity to tumor cells or antigen-expressing cells within the tumor microenvironment. Alpha-emitting radioisotopes have a short range of activity and high energy transfer and, when targeted, allow for precise killing of cancer cells with minimal damage to surrounding healthy tissues. Under this agreement with Inhibrx, NorthStar will support the development of a prespecified number of Inhibrx's novel biologic products by providing the Ac-225 supply and access to its integrated radiopharmaceutical contract development and manufacturing organization services. NorthStar will also prepare Inhibrx patient doses for clinical studies and, upon approval, may manufacture and supply radionuclides for Inhibrx's commercial use.

08:54 EST BMW says company doubled EV sales in 2022, targets BEVs at 15% of total in 2023 - In a LinkedIn post, BMW Group states: "We at the BMW Group more than doubled our fully electric vehicle sales last year BMW MINI and we already have our eyes set on our next milestone for 2023: 15% BEV share of total vehicle sales."

08:50 EST Antero Midstream subsidiary awarded $242M in damages in Veolia Water suit - In a regulatory filing, the company states: "As previously disclosed, a subsidiary of Antero Midstream (AM) was involved in a lawsuit with Veolia Water Technologies (VEOEY) in the district court of Denver County, Colorado relating to Antero's Clearwater Treatment Facility. On January 3, 2023, the Court found that Antero Midstream's subsidiary had prevailed on its claims for breach of contract and fraud, and awarded approximately $242 million in damages to Antero, plus pre- and post-judgment interest and reasonable costs and attorneys' fees. The Court also found in Antero's favor on all of Veolia's affirmative claims. The Court has yet to enter judgment on its findings, but any such judgment will be subject to appeal."

08:47 EST Omniq's Q Shield Safe City System to be deployed in two cities in Iowa - OMNIQ announced that the Company has been selected by the Cities of Mitchellville, Iowa and Jewell, Iowa to deploy its Q Shield Safe City System, based on vehicle recognition systems technology and its cloud based citation management platform.

08:45 EST Flux Power reports $26.9M customer order backlog as of Sept. 30 - Flux Power Holdings issued a letter to shareholders from Ron Dutt, CEO of Flux Power. "Throughout calendar year 2022, Flux Power continued its record of high growth while executing key initiatives to address supply chain disruption and accelerate our path to cash flow breakeven. The year was highlighted by new purchase orders from installed and new customers, a reduction in backlog, and the addition of new lithium-ion battery packs. We ended 2022 with over 15,000 high performance battery packs in the field for lift trucks and other industrial equipment including airport ground support equipment, GSE, and stationary energy storage for EV charging. These accomplishments, as of last reported September 30 quarter, resulted in now 17 consecutive quarters of year-over-year revenue growth, record gross margin, and a $26.9 million customer order backlog. customer order backlog...We continue to leverage our first mover position in lithium-ion adoption with our growing list of new and diverse Fortune 500 customers. Our commitment, consistent performance and trustworthiness are the foundation for long-term, sustainable relationships with our customers. In fact, our emphasis on building strong partnerships with our existing customers has enhanced our order volume, with nearly 90% of revenue during the third quarter attributed to customers with whom we have had long-term relationships. We expect our installed base customers will continue adopt lithium-ion packs for their fleet needs, reflecting customers patterns of ordering new forklifts. Expanding revenues from these relationships help drive new customers to our technology. Looking ahead into 2023, we believe 2023 should be a milestone year for Flux Power as we continue our growth trajectory, encouraged by strong purchase orders, improving backlog and continued expansion of margins through improved sourcing and supply chain management, continual process improvement, and pricing. At the same time, we will be advancing our technology, capacity, and customer and partnership relationships to support scaling our business. We thank all our shareholders for your ongoing support as we work diligently to build on the short and long-term value of our company and look forward to seeing some of you at our on-site investor day planned to take place within the coming months.

08:43 EST SKYX Platforms debuts SkyPlug Smart at CES 2023 - SKYX Platforms announces the worldwide debut of SkyPlug Smart, a smart lighting base that enables easy and safe plug & play installation of light fixtures and ceiling fans to the ceiling in just seconds, without touching hazardous wires. The product will be introduced at CES 2023 in Las Vegas, Jan. 5-8.

08:39 EST Visionary Education appoints Fan Zhou as CEO, John Kuhn as COO - Visionary Education Technology Holdings announced the Company's Board of Directors appointed founder, majority shareholder, and member of the Board, Executive Director, Fan Zhou as CEO, effective as of December 14, 2022. The Board also elected Mr. John Kuhn as the Company's COO and Executive Vice President. Mr. Guiping Xu resigned from the Company's CEO role as of December 14, 2022. Zhou was CEO from April 1, 2020 to October 31, 2020. Ms. Zhou served as a director from August 20, 2013 and as Executive Director from March 24, 2021 until December 15, 2021, and from June 17, 2022 to present. Kuhn has been the CFO of CyberDefense AI, which is a cyber security company offering firewall services.

08:38 EST 180 Life announces publication of review on biological basis of Dupuytren - 180 Life Sciences announced the publication of a review entitled 'Dupuytren's disease: a localized and accessible human fibrotic disorder' in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe the biology of Dupuytren's disease, to which they have made important contributions. The authors describe the genetics of this highly heritable disorder, the cellular mechanisms, the intercellular interactions and the key role of low-grade chronic inflammation in the pathogenesis of the disorder. One of the most important findings is that the mechanisms underlying the development of fibrosis in the hand are very similar to those in internal organs such as the lung in idiopathic pulmonary fibrosis. Dr. James Woody, CEO of 180 Life Sciences, stated, "Treatment of early-stage Dupuytren's disease represents a huge unmet medical need, and at 180 Life Sciences we are delighted to be advancing the pioneering work of Prof. Nanchahal and his team who are developing the use of anti-TNF hopefully for the benefit of the millions of patients affected by early-stage Dupuytren's disease, for which there is no approved treatment."

08:36 EST Ostin Technology to showcase independently developed products at CES 2023 - Ostin Technology Group announced it will attend the Consumer Electronics Show 2023 to be held from January 5 to 8, 2023 in Las Vegas, United States. The Company will showcase its portable panel and all-in-one PC products, and the two independently developed new products - Pintura photo-sharing and video conference products at the global trade show.

08:35 EST Eterna appoints angel as CEO, President - Eterna Therapeutics announced the appointment of Matt Angel, Ph.D. as Chief Executive Officer, CEO, and President. Dr. Angel has served as Interim CEO and President of Eterna since May 2022 and will continue to serve on the Company's Board of Directors. Dr. Angel joined Eterna as Interim CEO and President in May 2022 and was appointed a member of the Board of Directors. In addition to his role at Eterna, Dr. Angel serves as Co-Founder, Chairman and CEO of Factor Bioscience Inc., and Co-Founder and Scientific Advisory Board Chair of Exacis Biotherapeutics.

08:33 EST Neogames obtains WLA Responsible Gaming certification - NeoGames announced that it has attained the World Lottery Association, WLA, Responsible Gaming certification. This global accreditation confirms that NeoGames has achieved full alignment with the WLA responsible gaming standards for Lottery suppliers. The WLA responsible gaming standards framework was created to minimize the impact of problem gaming. With the awareness of the ever-increasing role that responsible gaming plays in lottery supplier operations, the WLA established an RG standard adapted to meet the specific needs of WLA members. "We are proud to have qualified for Responsible Gaming certification by the WLA, recognizing its importance to our customers and the demand for alignment with industry standards. Responsible gaming is deeply rooted in every facet of NeoGames' operations, from our products to our services and our employees, this certification confirms our continued commitment to being a responsible iLottery supplier." NeoGames CEO Moti Malul

08:32 EST Genasys secures GEM, evacuation software services contract from Utah counties - Genasys announced a Genasys Emergency Management, GEM, and Zonehaven software-as-a-service contract from three contiguous Utah counties. Genasys replaced competitors' emergency notification systems. "Eastern Utah counties Daggett, Duchesne and Uintah join 39 counties in five Western states employing Genasys public safety software services under multi-year contracts to better protect their residents during disasters and critical events," said Richard Danforth, Chief Executive Officer, Genasys Inc. "A national monument, a large dam in a national recreation area, and extensive oil and natural gas production facilities are located in these Utah counties. Emergency management officials will use GEM and Zonehaven to alert and evacuate people endangered by wildfires, flooding, oil and natural gas incidents, and other life safety hazards."

08:31 EST OneMedNet files amendment to Form S-4 on Data Knights Acquisition combination - OneMedNet has continued the process to become a publicly-listed company through a merger with Data Knights Acquisition Corp. when Data Knights submitted its second amendment to its Form S-4 with the Securities and Exchange Commission. OneMedNet and Data Knights announced their definitive merger agreement on April 25, 2022. Upon closing of the transaction, which is anticipated to occur in the first quarter of 2023, OneMedNet will become a publicly listed company and is expected to trade on the Nasdaq Global Select under the symbol "ONMD." In support of closing the merger, as previously announced, on November 11, 2022, Data Knights held a virtual special meeting. At the special meeting the stockholders approved the Extension Amendment Proposal, giving Data Knights the right to extend the date from November 11, 2022 by up to nine one-month extensions to August 11, 2023. Additionally, at the special meeting the stockholders approved the amendment to Data Knights' Investment Management Trust Agreement to extend the date on which Continental Stock Trust & Transfer must liquidate the Trust Account established in connection with Data Knights' IPO if Data Knights has not completed its initial business combination, from November 11, 2022 to August 11, 2023. The Registration Statement contains a preliminary proxy statement and prospectus, in connection with OneMedNet's previously announced proposed business combination with Data Knights. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about OneMedNet and the proposed business combination with Data Knights.

08:26 EST Aclara Resources provides 2023 outlook - 2023: Outlook: Proceeding with NI 43-101 Feasibility Study for the Penco Module in Q1; Environmental permit application for the Penco Module expected to be submitted in Q2; Social dialogue to continue: Evaluation of community requests during H1; Pilot plant expected to be in operation during Q3; Drilling in Chile and internationally expected to provide positive results; Definition of a potential second module: Exploration results to be reported in Q1; Exploring for potential international expansion; Overall budget of US$25 million approved for the year; With a possibility to grow depending on exploration results; Communications with potential off-takers expected to evolve during the year; Target of commencing production at Penco Module in Q1 2026 maintained. Ramon Barua, CEO, commented: "The business case for heavy rare earths, especially Dysprosium and Terbium, continues to strengthen significantly. The demand for EVs is expected to grow very significantly, and the need from OEMs to secure a geopolitically independent supply chain for critical materials is becoming more evident every day. Also, the need for ensuring materials that have a low environmental impact, a low carbon footprint and are traceable is becoming a top priority for responsible companies. In that regard, Aclara has a clear plan to supply the market for permanent magnets used in electric vehicles at a time when market demand is expected to outpace supply. Our unique process that does not require explosives, crushing, milling, which uses a common fertilizer as reagent and is able to recirculate water with 95% efficiency and the fertilizer with 99% efficiency, and which is expected to revegetate all areas with native species, is an innovative way to supply clean rare earths. We are already receiving interest in our product from top companies in the world, which reflects that our commitment to our planet is shared by our existing and future stakeholders. The dialogue with the local community has been a top priority for us and we are pleased to have opened ourselves to them and have been receiving feedback as to how to improve. We are very pleased to be in Chile and are committed to a project which we believe will be beneficial to Penco and to the environment. Finally, we have also started to explore for ionic clays in other countries with the goal of potentially increasing production aimed towards a planet that will require as much clean rare earths as possible."

08:22 EST SeaChange announces launch of its Xstream platform - SeaChange International announced the launch of the SeaChange Xstream platform, a cloud-based content monetization platform helping OEMs and content owners maximize advertising revenue on Connected TVs, CTVs. SeaChange is formally launching the Xstream platform on January 6th and will start onboarding customers as early as in the first quarter of the new fiscal year. "We are thrilled to launch the Xstream platform, a comprehensive service that capitalizes on the rapid consumer shift to the FAST and CTV markets," said Chris Klimmer, President of SeaChange. "As a leading technology vendor, SeaChange combines the deep expertise needed to provide premium user experiences on connected devices, a DNA to deliver end-to-end streaming solutions, and an unmatched product suite for smart ad insertion management.

08:21 EST Replimune Group appoints Chris Sarchi as CCO, Sushil Patel as CSO - Replimune Group (REPL) announced the appointment of Christopher Sarchi as Replimune's Chief Commercial Officer and the appointment of Sushil Patel, Ph.D., previously Replimune's Chief Commercial Officer, to a newly created position of Chief Strategy Officer, effective immediately. Chris joins Replimune having recently served as Head of Commercial U.S. Oncology at Sanofi (SNY) where he was responsible for several launches, including the launch of Libtayo as a new standard of care treatment for CSCC.

08:20 EST Immutep achieves 50% enrollment milestone in Phase IIB TACTI-003 trial - Immutep (IMMP) announces that it has enrolled and randomized over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial. TACTI-003 is evaluating Immutep's first-in-class soluble LAG-3 protein eftilagimod alpha, in combination with Merck & Co's (MRK) anti-PD-1 therapy KEYTRUDA as 1st line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Marc Voigt, CEO of Immutep stated: "We are pleased to reach this important milestone and extend our sincere appreciation to our investigators, clinical team, partners, and most importantly patients, that have participated in this study. As clinical evidence showing the compelling benefits of combining efti with immune checkpoint therapies such as pembrolizumab continues to grow, we are increasingly excited about efti's potential to safely deliver superior clinical outcomes and meaningfully expand the population of cancer patients that respond to treatment." The 1:1 randomised, controlled multinational TACTI-003 trial is currently accruing patients at over 25 centers in the United States, Australia, and Europe, and is expected to be fully recruited by mid-2023. Based largely on the promising data in 2nd line HNSCC from the Phase II TACTI-002 trial, including encouraging overall response rates regardless of PD-L1 expression and five complete responses, eftilagimod alpha was granted Fast Track designation by the FDA in April 2021 for treatment of 1L HNSCC.

08:18 EST Orion Energy appoints McDulin to board of directors - Orion Energy Systems announced that it has increased the size of the board to six members and appointed Charles McDulin to its board of directors effective immediately. McDulin is an investment analyst at Philotimo Fund, LP, a hedge fund focused on small-cap value and affiliated with Kanen Wealth Management, LLC.

08:17 EST Vislink receives over $2M in new airborne downlink orders from U.S., Canada - Vislink announced that it has recently received orders valued in excess of $2 million for HD airborne video downlink system, AVDS, equipment from law enforcement agencies in the U.S and Canada. The orders are comprised of comprehensive, automated surveillance and observation transmission and receive systems, long-range tactical handheld devices, as well as related componentry and managed client support services. "These orders underscore our commitment to fulfilling the stringent requirements of local, national and international military and law enforcement organizations," said Mickey Miller, CEO of Vislink. "Vislink continues to be a trusted law enforcement supplier for downlink systems that deliver real-time actionable intelligence in the most demanding operating environments. Over technology has long been field-proven to provide the critical tactical insights and multi-agency interoperability needed to ensure mission success." He added, "We are especially pleased that these recent contracts include orders for the AeroLink transceiver, which helps ensure our downlink systems deliver outstanding video quality, secure, full-duplex, real-time connectivity and extensive operating ranges."

08:16 EST Ascendis Pharma announces online portal open to request access to TransCon PTH - Ascendis Pharma announced that the online portal is now open for physicians wanting to request access to TransCon PTH, the Company's investigational parathyroid hormone replacement therapy, through the U.S. Expanded Access Program. To qualify, patients must be adults diagnosed with hypoparathyroidism who live in the U.S., have prior PTH treatment experience, and meet other criteria outlined below and in the full treatment protocol. "We are pleased to have worked with the FDA to make TransCon PTH available for eligible patients in the U.S.," said Edward Trott, M.D., Vice President, Global Medical Affairs at Ascendis Pharma. "Recognizing the needs expressed by the hypopara community, we will continue to work with the FDA and others to make TransCon PTH, if approved, more broadly available as quickly as possible."

08:14 EST Tenax Therapeutics announces 1-for-20 reverse stock split - Tenax Therapeutics announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 5:00 pm Eastern Time on January 4, 2023. The Company's common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis beginning upon market open on January 5, 2023, under the Company's existing trading symbol "TENX". The reverse stock split was previously approved by the Company's stockholders at the annual meeting of stockholders held on June 9, 2022, with the final ratio determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with Nasdaq's minimum bid price requirement. The new CUSIP number following the reverse stock split will be 88032L506.

08:13 EST Cerence announces continued strategic partnership with what3words - Cerence and what3words announce their continued strategic partnership to supply their voice-powered navigation solution to leading automakers around the globe. The number of cars on the road with the companies' joint solution has doubled in two years, demonstrating ongoing adoption from the world's leading automakers as they look to simplify the in-car navigation experience for their drivers. The companies said, "As long-term partners, Cerence and what3words have built impressive momentum in the global automotive sector, partnering with major brands, including VinFast, Mercedes Benz, and Tata Motors. The latest automaker to deploy the companies' joint solution is Subaru, who recently announced the rollout of Cerence and what3words' voice-powered navigation in both the US and Japan. Subaru is the first car manufacturer to launch what3words voice entry in Japanese."

08:12 EST FOREWARN partners with Columbus REALTORS - FOREWARN announced that Columbus REALTORS & Columbus and Central Ohio Regional MLS have contracted to make FOREWARN services available for the 9,000+ REALTOR members they serve throughout the Columbus area to promote proactive real estate agent safety.

08:10 EST LifeMD appoints Friedeman as Chief Marketing Officer - LifeMD announced the appointment of Jessica Friedeman as Chief Marketing Officer, CMO. Friedeman succeeds Stefan Galluppi, who continues as LifeMD's Chief Innovation Officer. Friedeman brings nearly twenty years' experience engaging and retaining patients. Friedeman has served as a leader in roles of increasing responsibility and impact through several acquisitions, including most recently as Chief Marketing Officer of Healthgrades.

08:10 EST Bentley Systems announces Brock Ballard as Chief Revenue Officer - Bentley Systems announced that Brock Ballard, previously vice president and regional executive, Americas, has been promoted to the role of Chief Revenue Officer, and that Eric Boyer has joined as Investor Relations Officer. Ballard succeeds newly retired Gus Bergsma who joined with Bentley Systems' acquisition of RAM International in 2005. Prior to joining Bentley Systems in 2020, Ballard served in sales leadership positions with Dassault Systemes, Autodesk, and Oce after earning a Bachelor of Arts in Communications and Information Sciences from the University of Alabama in 2001.

08:09 EST Chart Industries, BNG execute MoU for hydrogen liquefaction, equipment supply - Chart Industries and BNG Clean Fuel Corporation announced their executed Memorandum of Understanding, MoU, for Chart to supply the hydrogen liquefaction process technology, associated equipment as well as a series of hydrogen fuelling stations. Additionally, the companies will collaborate to develop further industry relationships with customers in the end-use industries described above to utilize BNG's "hub, spoke and wheel model" facilities for hydrogen production, virtual pipeline networks, bulk cargo shipping, and fuel dispensing stations. BNG is focused first on their DenverH2 pilot hub with dual-22 ton per day capacity hydrogen liquefaction facilities, a centrally located storage terminal, 10 liquid hydrogen stations, tankers and mobile fuelling equipment which will be provided by Chart. While no orders have been booked at Chart related to this MOU or project, they are anticipated to be booked in 2023 and 2024 for both the equipment and process technology scope. "BNG is taking a pragmatic approach to scaling of the hydrogen economy, with a focus on the hub and spoke model starting in North America," stated Jill Evanko, Chart's CEO and President. "This MOU brings Chart's extensive technology and equipment experience to the project. We look forward to supporting BNG's endeavors to deliver another option to the hydrogen end-use market."

08:08 EST Cidara Therapeutics nominates first oncology candidate from Cloudbreak platform - Cidara Therapeutics announced that it has selected its first oncology drug-Fc conjugate, DFC, candidate from the company's Cloudbreak platform: CBO-212, targeting CD73. "We are excited to start the new year by announcing CBO-212 as our first oncology DFC, marking a significant inflection point for Cidara and our Cloudbreak platform," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "With our Cloudbreak oncology program we seek to develop a new generation of immunotherapies, and our CBO-212 DFC is a first-in-class CD73 inhibitor that combines the strengths of small molecules and monoclonal antibodies targeting CD73. We look forward to advancing CBO-212 through IND enabling studies and providing updates on its progress in leading conferences as we continue to generate more data."

08:06 EST Nuvectis Pharma announcse collaboration with ENGOT, GOG Foundation - Nuvectis Pharma announced a collaboration with the European Network of Gynecological Oncology Trial Groups, ENGOT, and the GOG Foundation to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States. "We are honored to collaborate with the ENGOT and GOG-F on this very important clinical trial. ENGOT and GOG-F are the world's premier gynecology oncology clinical trials consortia, representing some of the leading medical centers and having spear-headed several drug approvals in the field, including the 2 PARP inhibitors for the treatment of BRCA-mutated ovarian cancers, Olaparib and Niraparib, as well as the antibody-drug conjugate Tivdak, which is approved for cervical cancer," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Bentsur continued, "As our Phase 1a dose-escalation study in patients with advanced solid tumors is nearing completion, we have begun preparing for the start of the Phase 1b trial alongside the consortia's world renowned experts who provide guidance into key design elements of the study protocol and access to top clinical centers." Bentsur added: "We believe that the high-quality discovery and lead optimization program at the Institute of Cancer Research, the robust preclinical proof of concept, the recent Fast Track Designation by the U.S. FDA, and now the collaboration with ENGOT and GOG-F, bode well for the future of NXP800. Clinical data from the ongoing Phase 1a trial to date suggest that the emerging clinical profile of NXP800 can provide a good balance between systemic exposure, pharmacodynamic activity and tolerability, and we look forward to the initiation of the Phase 1b trial in the next few months."

08:05 EST Checkpoint Therapeutics submits BLA to FDA for cosibelimab - Checkpoint Therapeutics announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for the approval of cosibelimab, its investigational anti-PD-L1 antibody, as a treatment for patients with metastatic cutaneous squamous cell carcinoma, cSSC, or locally advanced cSCC who are not candidates for curative surgery or radiation. "This is a major milestone for Checkpoint Therapeutics, representing our first submission of a marketing application for one of our investigational medications and furthering our evolution from a development-stage company to a fully integrated commercial organization to support the potential launch of cosibelimab," said James Oliviero, President and Chief Executive Officer of Checkpoint. "cSCC is the second most common type of skin cancer in the United States. While most cases involve localized tumors amenable to curative resection, approximately 40,000 cases will become advanced, and an estimated 15,000 people will die from their disease each year. Based on its compelling and differentiated product profile and the positive data generated to date, we believe cosibelimab has the potential to be an important treatment option for patients. Importantly, we continue to plan for cosibelimab to be positioned, upon regulatory approval, as potentially the first and only price disruptive PD-1/PD-L1 inhibitor in the U.S. market." Mr. Oliviero continued, "We want to thank the patients and their families, as well as the physicians and their research teams, who participated in our trial and contributed immensely to the advancement of cosibelimab." The BLA submission is based on positive efficacy and safety results from Checkpoint's ongoing registration-enabling, multi-regional, multicohort clinical trial evaluating cosibelimab administered as fixed doses of either 800 mg every two weeks or 1200 mg every three weeks in patients with selected recurrent or metastatic cancers, including pivotal cohorts in metastatic and locally advanced cSCC.

08:05 EST Galmed reports results from Open-Label Part of the ARMOR study - Galmed reported full results from the Open-Label Part of the ARMOR study corroborating effects of Aramchol across all efficacy parameters. The study enrolled 157 subjects with biopsy-proven NASH randomized 1:1:1 into three groups differing in the timing of the post-baseline liver biopsy (Week 24, Week 48, and Week 72). Fifty-one (51) subjects underwent post-baseline biopsies prior to study discontinuation (28 subjects at less than48 weeks and 23 subjects at greater than or equal to48 weeks). The study was designed to assess the safety, pharmacokinetics and efficacy kinetics as a function of treatment duration. Three independent pathologists and three different histopathology reading methodologies were used to assess the antifibrotic effect of Aramchol: fibrosis stage based on NASH CRN; ranked assessment (improvement/worsening/stable) of paired (pre- and post-baseline) biopsies, blinded to sequence; and an automated and continuous score of Fibrosis Composite Severity, using FibroNest, a quantitative AI digital pathology image analysis method. Noninvasive tests (NITs) included imaging (fibroscan) and biomarkers (liver enzymes, FIB-4, Pro-C3 and ELF). Aramchol treatment resulted in a high proportion of subjects showing fibrosis improvement based on all three biopsy reading methodologies, with a larger treatment effect with longer duration of therapy. Following a treatment duration of 48 weeks or more, improvement in fibrosis was demonstrated in 39% of subjects according to NASH CRN and 61% of subjects according to ranked assessment. At Week 48 AI demonstrated fibrosis improvement in 100% of subjects when responders were defined by an absolute reduction of the FCS score greater than0.3, 65% when responders were defined by a relative reduction of greater than25%, and a statistically significant reduction from baseline in mean FCS score (pless than0.0001). NASH resolution without worsening of fibrosis was demonstrated in 26.5% of subjects. Fibroscan, ALT, AST, and FIB4 were analyzed using MMRM, based on all subjects (N=154). Fibroscan results were consistent, with an improvement in fibrosis showing a mean absolute reduction from baseline to week 72 of 2.5 kPa (pless than0.0001). At Week 72, ALT was reduced by 22 U/L (pless than0.0001), AST was reduced by 18 U/L (pless than0.0001), and FIB-4 was reduced by 0.30 (pless than0.0001). Pro-C3 and ELF were analyzed for 43 subjects at week 24 showing reduction in both Pro-C3 levels (pless than0.0001) and ELF (p=0.0038). The Open Label part demonstrated the good safety profile of Aramchol 300mg BID including long-term follow up. The incidence of serious adverse events was consistent with the population (10.4%) and early discontinuation rates due to adverse events were low (4.5%).

08:03 EST Jasper Therapeutics announces EMA ODD for briquilimab - Jasper Therapeutics announced that the European Medicines Agency, EMA, Committee for Orphan Medicinal Products, COMP, has granted orphan drug designation, ODD, to briquilimab, formerly known as JSP191, a monoclonal antibody targeting the CD117, receptor, for conditioning treatment prior to HCT. Previously, the U.S. Food and Drug Administration granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency. "The EMA's decision to grant orphan drug designation to briquilimab highlights the clear need for non-genotoxic, targeted conditioning for patients receiving hematopoietic stem cell transplant," said Ronald Martell, President and Chief Executive Officer of Jasper Therapeutics. "Transplants have the potential to cure several hematologic cancers and genetically inherited diseases. However, the toxicities associated with genotoxic conditioning needed to prepare patients for these procedures often limit their use. We believe that briquilimab has the potential to fill this gap, effectively expanding access to curative stem cell transplant across a range of indications. With the orphan designation, the EMA has demonstrated support of briquilimab in Europe and Jasper is committed to advancing this therapy globally."

08:01 EST SVB Financial names Kim Olson as Chief Risk Officer - SVB announced the appointment of Kim Olson as Chief Risk Officer. In this role, Olson will lead the Risk function and team, developing and maintaining SVB's risk management framework and a culture of risk management across the company. Olson has thirty years of financial services experience. She joins SVB from Sumitomo Mitsui Banking Corporation, where she served as the Chief Risk Officer for SMBC in the Americas, and an Executive Officer of SMBC and Sumitomo Mitsui Financial Group.

07:56 EST Sonoma Pharmaceuticals launches line of office dispense products for skin care - Sonoma Pharmaceuticals announced that it has launched a line of office dispense products exclusively for skin care professionals. The products include Regenacyn Plus, Reliefacyn Plus, and Rejuvacyn Plus, all in prescription strength formulations. Sonoma is targeting its office distribution program to dermatology practices and medical spas. Clients will be able to purchase Sonoma's prescription strength products directly from their skin care professional, instead of making a separate trip to the pharmacy. Office dispense offers improved outcomes, convenience, and lower healthcare costs for clients while providing an additional source of income for skin care professionals.

07:55 EST Theratechnologies focused on achieving positive EBITDA in the near-term - CEO Paul Levesque said, "While we refine our plans around TH1902, our priority will be to rein in costs associated with its development and deploy those resources towards the Company's path to positive cash flow from operations in 2023. In doing so, we believe that we will be able to generate increasing cash flow throughout the year, which will give us further leverage to build upon our commercial portfolio. For future consideration, we have tasked our business development team to explore opportunities for additional commercialized assets which can be incorporated into our existing product portfolio, leveraging the strength of our commercial infrastructure in the United States. We will remain laser-focused on continuing to build out our strong commercial portfolio, significantly improving patient care in the HIV space along the way, while continuing to pursue development opportunities in a financially responsible manner."

07:52 EST Theratechnologies CEO says positioned 'product portfolio for commercial success' - CEO Paul Levesque siaid, "We have been especially pleased with our FY2022 results, having worked to position our product portfolio for commercial success. We built out a dedicated salesforce in-house, removing our reliance on external contract organizations. This move has resulted in accelerated sales growth. We are working towards driving long-term, sustainable, double-digit sales growth with an eye on achieving positive cash flow from operations in the near-term. Our medicines are also becoming more and more embedded in the workflow of prescribers as an option of choice that can play a major impact in the lives of people living with HIV. During 2022, we also worked diligently to further improve Trogarzo's method of administration and now have FDA approval for Trogarzo's 30-Second Intravenous Push administration, simplifying the method of administration for heavily treatment-experienced populations. We are also working closely with our partner, TaiMed Biologics, in completing the development of an intra-muscular method of administration for Trogarzo, and subsequent filing of a new supplemental Biologics License Application with the FDA. These projects will serve to ensure lifecycle management of Trogarzo for years to come. In HIV-associated lipodystrophy, we are on track to complete the Human Factors Study for EGRIFTA SV in the first half of 2023, and we are diligently completing the work associated to the sBLA filing for the F8 formulation of Tesamorelin with the FDA. We are also confident in successfully addressing the shortage of bacteriostatic water for injection by placing the sourcing of this drug component under our own control via the services of a third-party manufacturer. The further development of Tesamorelin allows Theratechnologies to maintain its positioning as one of the few options for drug developers to immediately partner with a company in order to launch a Phase 2b/3 NASH clinical trial. Operationally, we made the difficult decision to withdraw our business from Europe in order to focus sales in the United States, a territory with optimal conditions for growing our commercial assets. Withdrawing from Europe was a difficult but necessary decision as it represents a region with unfavorable pricing regimes across many territories. Both the NASH and HIV markets in the United States have considerable opportunity, and we believe that we are well positioned to capture market share in the future."

07:47 EST FTI Consulting announces expansion of FTI Capital Advisors - FTI Consulting announced the continued expansion of FTI Capital Advisors with the addition of Rod Rivera as a Senior Managing Director and David Baker and Roger Kahn as Managing Directors. The New York- and Denver-based team, who join FTI Capital Advisors from Capstone Partners, will advise clients in healthcare, with a focus on M&A and financing transactions. The trio has current assignments in physician practice management, medical equipment sales and services, pharmaceutical benefit management, healthcare staffing and government services, medical technologies and healthcare information technology. Rivera served as a Managing Director in Capstone Partners' Healthcare Group, providing financing and M&A solutions for clients with a focus on healthcare services, including provider and payor, post-acute and pharma services. Prior to joining FTI Capital Advisors, Mr. Baker was co-head of Capstone Partners' Healthcare Group and held senior positions at Lazard and GE Healthcare. Kahn most recently served as a Managing Director in the Healthcare Group at Capstone Partners and brings more than 35 years of experience in M&A and financings.

07:45 EST NFI Group receives contract for up to 166 zero-emission buses - NFI Group announced that its subsidiary New Flyer Industries Canada ULC has received new firm orders for 16 battery-electric and fuel cell-electric transit buses from Winnipeg Transit. The contract also has options to be extended for up to four years to purchase up to 150 40-foot zero-emission buses. In total, NFI will add up to 166 buses to its backlog from firm and option orders. The new five-year contract includes the following firm orders: Four Xcelsior CHARGE FC fuel cell-electric 40-foot, heavy-duty transit buses, and four Xcelsior CHARGE FC fuel cell-electric 60-foot transit buses, and Four Xcelsior CHARGE NG battery-electric 40-foot transit buses and four Xcelsior CHARGE NG battery-electric 60-foot transit buses.

07:44 EST OptimizeRx CEO issues open letter to shareholders - OptimizeRx announced OptimizeRx's CEO Will Febbo is invited to speak at the upcoming J.P. Morgan Healthcare Conference. Ahead of the conference, OPRX is providing the following business update and key industry trends from management's presentation. "Our key strengths which we expect will propel OPRX in 2023 include: Our network reach of more than 60% of active prescribers; Continued expansion of omnichannel communication capabilities to build cutting edge solutions; Staying at the leading-edge of connecting touchpoints to both healthcare providers and patients; AI-enablement which identifies HCPs whose patients are most in need of our customers' resources and therapies. In the new year, we remain committed to leveraging innovation to improve patient journeys and outcomes through the intelligent convergence of healthcare data and technology across the OptimizeRx platform.... We will continue to be the leader in advancing the application of AI driven by RWE for the purposes of predicting the healthcare resource and therapy needs of HCPs and patients. We are setting a new standard for unparalleled ROI and improved patient outcomes. At the heart of this success through innovation, our AI/RWE business pipeline remains strong, and we continue our work with the biggest pharma brands in the industry through existing, extended, and new deals... Our POC messaging includes delivery of cost-saving resources to help make therapies affordable, something we have always done, and continue to do well; it is now even more effective with the application of RWE to find the most appropriate healthcare provider targets. Additionally, we have proven out the new standard for ROI and patient outcomes through finding unique patients best suited for novel therapies... In 2023, we will further demonstrate our ability to integrate our products and solutions with business enterprises with a greater shift away from tactical to solution-based selling, of which our AI/RWE deals are illustrating. In doing so, we are cementing scalable tech partnerships with our clients and strengthening our path forward to profitability."

07:40 EST Context Therapeutics expects cash to fund operations into Q1 of 2024 - The Company had cash and cash equivalents of $39.4 million as of September 30, 2022. The Company expects its current level of cash and cash equivalents will enable the Company to fund its operations into Q1 2024.

07:40 EST Jack Creek Investment reschedules extraordinary meeting of shareholders - Jack Creek Investment announced the rescheduling of Jack Creek's extraordinary general meeting of shareholders originally scheduled to be held on January 10, 2023. The EGM has been rescheduled for January 12, 2023 at 10:30 a.m. Eastern Time. The deadline for holders of Class A ordinary shares to request that Jack Creek redeem all or a portion of their shares is, accordingly, January 10, 2023 at 5:00 p.m. Eastern Time. As previously announced, the EGM will occur at the offices of Weil, Gotshal & Manges LLP located at 767 Fifth Avenue, New York, NY 10153. The EGM is being held to vote on the proposals described in the definitive proxy statement, filed with the Securities and Exchange Commission on December 20, 2022 by Jack Creek relating to the potential business combination between Bridger Aerospace Group Holdings and Jack Creek and related transactions. The record date for the determination of shareholders entitled to vote at the EGM, including all adjournments thereof, remains November 30, 2022. The Jack Creek Board of Directors recommends that shareholders vote in favor of the proposals.

07:39 EST Certara acquires AI company Vyasa, terms not disclosed - Certara announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The company said, "The acquisition will elevate Certara's software by bringing state-of-the-art artificial intelligence capabilities to its end-to-end platform. Formed in 2017, Vyasa software provides a novel AI-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. Vyasa's leading product, LAYAR, a flexible and modular data fabric that evaluates quantitative data, text, and images, offers AI capabilities to support decisions in all phases of drug development."

07:38 EST Marathon Gold announces exploration priorities during Valentine construction - Marathon Gold provides an overview of the Company's exploration priorities during the upcoming two-year period of mine construction at the Valentine Gold Project located in central Newfoundland. The Project was approved for construction in September 2022 and early works commenced in October 2022. An Updated Feasibility Study was completed in December 2022, describing for the first time a 3-pit mine plan based on the Marathon, Leprechaun and Berry Deposits, with increased Mineral Reserves, an extended mine life, and a higher gold production profile. First ore is scheduled to be delivered to the mill in late 2024, with production ramp-up scheduled for the first quarter of 2025. As mine construction moves forward, Marathon intends to maintain a focus on exploration based on the following two priorities: delivering more ounces of mineable gold mineralization within the scope of the existing 3-pit mine plan, and making new discoveries leading to new Mineral Resources on the Valentine property outside the scope of the current mine plan. Exploration activities contemplated during the two-year period of 2023-2024 are as follows: A 70,000 metre Reverse Circulation drill program at the Leprechaun, Marathon and Berry Deposits, with the objective of developing a grade control model to support early mine production reconciliation and forecasting, and building on the positive experiences of the 2021 RC drill program; Discovery-oriented exploration at the new Eastern Arm and Western Peninsula prospecting areas, with a view to establishing potential trenching and or drill targets for new mineralized deposits; Updated geological and mineralization models for the Berry Deposit integrating 2022 drill results, including drill results still outstanding, with a focus on new mineralization potential within the current mining pit shell; Updated geological and mineralization models for the Victory Deposit integrating 2021-2022 drill results, including drill results still outstanding, with the objective of expanding the mineral resource potential of Victory beyond its current estimate; Reassessment of known mineralized showings at the Valentine Property, such as the Frank Zone, with additional diamond drilling as warranted; and Exploration results incorporated into annualized Mineral Resource updates.

07:36 EST Virax Biolabs introduces HPV test kit - Virax Biolabs announced the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the company's sales representatives

07:35 EST Zhongchao: Xinjiang Pharmaceutical to distribute drugs of Natco Pharma in China - Zhongchao announced that Chongqing Xinjiang Pharmaceutical Co., one of the Chinese operating entities of which the company consolidates the financial results with through certain contractual arrangements, will act as the drug distribution agent of certain drugs produced by Natco Pharma Limited within Mainland China pursuant to certain agreements. Natco is a vertically integrated and R&D focused pharmaceutical company in India. Through this cooperation, Xinjiang Pharmaceutical will introduce different products from Natco based on the needs of patients in China, for example, anti-influenza drugs during the flu season, and high demand anti-tumor and anti-rare diseases products. Both parties will work together to apply registration certificate of imported drugs and submit filings of sales agent, and will fully leverage their advantages and resources to effectively shorten the clinical trial approval and other processes and accelerate the progress of introducing quality drugs to the patients in China.

07:33 EST Cryptyde announces 2023 corporate priorities - Cryptyde has announced its corporate priorities for the next 12 months. The company said, "Cryptyde currently has two main wholly-owned subsidiaries. Forever 8 is a cash flow management platform for e-commerce sellers, and Ferguson Containers is a provider of complete manufacturing and logistical solutions for product and packaging needs. Cryptyde plans to drive growth and innovation through the strategic expansion and management of these two main subsidiaries. Corporate priorities for Cryptyde in 2023, which are aimed at bridging the gap Cryptyde believes exists between the value of its business and its value as reflected in the equity markets, include: Identifying and prioritizing revenue-producing business opportunities and expansions that would be expected to drive growth and success. With a focus on cash flow management and EBIDTA, we will carefully evaluate potential opportunities and select those that align with our long-term objectives and provide the greatest potential for success. This may involve expanding into new markets, launching new products or services, or acquiring complementary businesses. Developing a strategy for efficiently acquiring capital for long-term growth. This may involve seeking out partnerships, seeking investments or utilizing debt financing. By increasing our access to efficient capital, we will be better positioned to scale our business, particularly Forever 8. Launching new software as a service products and services that drive revenue and profitability. By offering features from the Forever 8 platform as a service, as well as leveraging our existing infrastructure to launch new products and platforms, we believe we can create significant value for our customers and grow our profit margins. Identifying and evaluating potential acquisition targets to help us expand our existing business and launch new products and services. We believe that strategic acquisitions can be a powerful tool for driving growth and creating value and we are open to exploring opportunities that align with our long-term objectives and provide potential for success. Continuously monitoring market conditions and refining our strategy as needed to ensure that we remain competitive and well-positioned for growth. We are committed to staying nimble and responsive to new opportunities and challenges."

07:32 EST Blacboxstocks extends $2.5M stock buyback program - Blackboxstocks announced that it has extended its $2.5M stock buyback program to December 31. The buyback program was initiated in January 2022 with an initial expiration date of December 31, 2022. As of September 30, 2022, the company had repurchased 615,748 shares of its common stock at a total cost of $1,434,734. Stock purchases can be made from time to time using a variety of methods, including open market purchases or block trades, all in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements.

07:31 EST BrainStorm names Dr. Stacy Lindborg as co-CEO - BrainStorm announced the promotion of Dr. Stacy Lindborg to the role of Co-CEO. This promotion launches a targeted capability build which will be led by Dr. Lindborg, to hire and bring expertise inside BrainStorm, preparing for success. Dr. Lindborg, who joined BrainStorm in 2020 and is based in the U.S., brings to her expanded role more than 25 years of pharmaceutical industry experience in R&D, strategy development, regulatory, and analytics. She will work alongside Chaim Lebovits, who is retaining his position as President and CEO. In addition, Dr. Ralph Kern will retire from his current role as President and Chief Medical Officer in January 2023 and will continue to support BrainStorm as part of the company's Scientific Advisory Board.

07:21 EST Laser Photonics fulfills third order for customer for CleanTech laser system - Laser Photonics announced it recently received and fulfilled the second follow-on order over the past 12 months from the same major truck manufacturer, bringing this customer's total purchases to three CleanTech laser systems.

07:17 EST Electra Battery Materials disposes non-core Canadian mineral properties - Electra Battery Materials announced it has signed an amendment to a 2021 share purchase and option agreement with Kuya Silver Corporation relating to silver and cobalt exploration assets in the Canadian Cobalt Camp. Electra has granted to Kuya the right to acquire a 100% interest in its remaining assets in the Canadian Cobalt Camp. To exercise this right, Kuya is required to make a payment in cash or in the equivalent value of its shares totaling $1M to Electra on or prior to January 31, 2023. The equivalent value of Kuya's shares will be based on the share price equivalent to the earn-in volume weighted average price prior to the issuance. Kuya has also agreed to enter into a royalty agreement with Electra whereby it will grant Electra a two percent royalty on net smelter returns from commercial production derived from the remaining assets. Electra will retain a right of first offer to refine any base metal concentrates produced from the Assets at Electra's Ontario refinery. Electra and Kuya first entered into a share purchase and option agreement on February 26, 2021 whereby Kuya acquired a 100 percent interest in the property package surrounding the Kerr Lake area for $4M and an option to earn up to a 70% interest in Electra's remaining assets for an additional $1M. Under the original agreement, Kuya was required to make $1M in additional payments and invest $4M in exploration activities. Pursuant to the terms of the Amendment, Kuya will also be assuming management of any ongoing obligations and liabilities associated with the Assets.

07:16 EST Lucira Health launches Lucira Connect in Canada - Lucira Health announced the Canadian launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the price of the test, excluding prescription costs. Lucira Connect is currently offered in British Columbia, Ontario and Alberta with plans to expand. "Rapid care from diagnosis to treatment is essential for managing you and your family's health and for reducing the spread of COVID-19 and Flu," said Erik Engelson, President and CEO of Lucira Health. "Since our inception, we have been driven to revolutionize the testing industry by offering accurate and accessible healthcare from the comfort and safety of your home. The Lucira Connect program is one of the fastest and simplest ways to learn if you have COVID-19 or the Flu, understand what you can do about it, and to access appropriate treatment if prescribed by a medical professional. Through these partnerships, we aim to help simplify the way people access reliable information about their health and navigate COVID-19 and Flu infections to improve outcomes."

07:14 EST Skyward Specialty Insurance launches initial public offering - Skyward Specialty Insurance Group announced the launch of its initial public offering of its common stock. The offering consists of 4,750,000 shares of common stock offered by Skyward Specialty and 3,750,000 shares of common stock to be sold by certain of Skyward Specialty's existing stockholders, plus up to an additional 1,275,000 shares to be sold by existing stockholders that the underwriters have the option to purchase. The initial public offering price is expected to be between $14.00 and $16.00 per share. The shares are expected to trade on the Nasdaq Global Select Market under the ticker symbol "SKWD." Skyward Specialty's principal purposes of the offering are to increase capitalization and financial flexibility and create a public market for its common stock, thereby enabling access to the public equity markets for the Company and its stockholders. Skyward Specialty intends to use a portion of the net proceeds from this offering to make capital contributions to its insurance company subsidiaries to grow its business, using the remainder for general corporate purposes. Skyward Specialty will not receive any proceeds from any sale of shares of common stock by the selling stockholders. Barclays Capital Inc. and Keefe, Bruyette & Woods, Inc. are acting as joint lead book-running managers for the proposed offering. Piper Sandler & Co., JMP Securities, A Citizens Company, Truist Securities, Inc., and Raymond James & Associates, Inc., are acting as joint book-running managers for the proposed offering. Academy Securities, Inc. and Siebert Williams Shank & Co. LLC are acting as co-managers for the proposed offering.

07:13 EST Origin announces Louisiana State Bond Commission approval for Origin 2 financing - Origin Materials announced that the Louisiana State Bond Commission has unanimously passed a resolution granting its final approval of the issuance of up to $1.5B of tax-exempt bonds for the financing for the construction of Origin 2, the company's first world-scale manufacturing facility, to be located in Geismar, Louisiana. Origin's use of solid waste feedstock to produce carbon negative materials enables the company to use these tax-exempt bonds towards financing the Origin 2 project. Bank of America, a global investment bank and financial services company, has been engaged by Origin to underwrite the bonds and market them to investors. Building on the strong foundation of the previously announced expected $400M in Private Activity Bond volume cap allocation, the Bond Commission has authorized issuing bonds of up to $1.5B, inclusive of the PAB cap, to support construction and commissioning of Origin 2. This could enable the debt financing of Origin 2 using entirely tax-exempt bonds. Origin also continues to work with leading financial institutions on other forms of traditional private financing and federal loan programs, including through the United States Department of Agriculture and Department of Energy, and to pursue other local, state, and federal incentives programs to optimize the financing of Origin 2, including certain 2021 Infrastructure Investment and Jobs Act and 2022 Inflation Reduction Act provisions. The bond commission approval follows the preliminary approval by unanimous resolution of the Louisiana Public Finance Authority board of trustees at its September 6, 2022 meeting, of the up to $1.5B bond issuance. The LPFA is a statewide conduit issuer of revenue bonds and is authorized to issue bonds to finance economic development, industrial and manufacturing facilities, and a variety of projects on behalf of local governmental entities throughout the State of Louisiana. Although the bond commission authorizes the issuance of the bonds, they are not guaranteed by the State of Louisiana nor the LPFA nor are taxpayer dollars involved.

07:12 EST Bausch + Lomb Novaliq announce GOBI trial met both co-primary endpoints - Bausch + Lomb and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics announced that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the pivotal Phase 3 trial GOBI, which is one of two pivotal Phase 3 trials for NOV03, perfluorohexyloctane. NOV03 is being investigated to treat the signs and symptoms of dry eye disease DED associated with Meibomian gland dysfunction MGD . The U.S. Food and Drug Administration FDA assigned NOV03 a Prescription Drug User Fee Act PDUFA action date of June 28 . "NOV03 was specifically developed to address excess tear evaporation and alleviate the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb. "These findings reinforce NOV03 as a potential new treatment option that is distinct from anti-inflammatory and immunomodulatory agents. We are excited that the FDA is reviewing the New Drug Application for NOV03, which, if approved, would provide millions of patients with dry eye disease associated with Meibomian gland dysfunction a prescription treatment option."1 DED is one of the most common ocular surface disorders, with MGD as a major cause of development and progression, affecting approximately nine out of 10 people with DED.2,3 DED due to MGD is caused by a deficient tear film lipid layer that leads to increased tear evaporation. There is currently no approved prescription eye drop in the United States indicated for DED associated with MGD. "These data show that the GOBI trial met both co-primary endpoints and all key secondary endpoints, with statistical significance achieved in treating the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction as early as day 15," said Christian Roesky, Ph.D., CEO, Novaliq. "We are pleased to be able to share these exciting findings in Ophthalmology, and we look forward to our continued collaboration with Bausch + Lomb to hopefully bring NOV03 to market in the United States, and ultimately address an unmet medical need for those suffering with dry eye disease associated with Meibomian gland dysfunction."

07:12 EST CollPlant announces 'successful' results in 3D bioprinted breast implant study - CollPlant announced that it has successfully completed a large animal study for its recombinant human collagen-based 3D bioprinted regenerative breast implants, addressing the $2.5B global breast implant market. Supported by these promising results, the company is planning to initiate a follow-up large animal study during 2023 using commercial-size implants to support subsequent human studies and future product commercialization. The study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective tissue and neovascular networks within the implants. No indication of adverse reaction was noted. Promising results support continued development of rhCollagen-based regenerative breast implants as a revolutionary and potentially safer and more natural alternative for aesthetic and reconstructive procedures, including postmastectomy for cancer patients.

07:10 EST Bruker, Biognosys form partnership for advanced proteomics CRO services - Biognosys and Bruker announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. Several of Biognosys' earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys. Co-Founder and CEO Dr. Oliver Rinner and his leadership team will continue to manage Biognosys as a world-leading proteomics and proteogenomics CRO services and proteomics software company. Going forward, Biognosys' biomarker and biopharma customers will benefit from additional services and footprint in the US. Biognosys will access Bruker's leading 4D proteomics timsTOF technology for deeper, unbiased high-precision proteomics that is not impaired by epitope cross-reactivity - all with higher throughput and excellent reproducibility. The Bruker-Biognosys collaboration is expected to create unique synergies between Biognosys' versatile portfolio of proprietary proteomics services, software and kits, and Bruker's pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States. Dr. Oliver Rinner, CEO and Co-Founder of Biognosys, commented: "We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development. We have worked closely with Bruker to support dia-PASEF high-throughput, deeper proteomics methods within our Spectronaut software. Biognosys remains committed to maintaining Spectronaut as a high-performance vendor-agnostic proteomics software. We plan to establish our US CRO lab in Massachusetts using the timsTOF platform, so that our customers can benefit from multiple MS technologies."

07:09 EST Bruker announces ownership investment in Biognosys, terms undisclosed - Bruker and Switzerland-based Biognosys announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys' earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys. The Bruker-Biognosys collaboration is expected to create synergies between Biognosys' versatile portfolio of proprietary proteomics services, software and kits, and Bruker's pioneering timsTOF platform. As a result of the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in the United States.

07:08 EST BioLineRx names Tami Rachmilewitz, M.D., as Chief Medical Officer - BioLineRx announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer. Dr. Rachmilewitz will report to the CEO and lead the company's clinical and medical functions. Her appointment is effective January 4, 2023. Dr. Rachmilewitz brings over 15 years of clinical development industry experience to the Company, including overseeing clinical development programs in oncology, immunology, and neurodegeneration. Previously, she was Senior Vice President of Clinical Development at VBL Therapeutics, where she led all aspects of the company's immuno-oncology clinical trial programs and oversaw its clinical operations and medical affairs teams.

07:07 EST Aravive complete enrollment in Phase 3 AXLerate-OC trial - Aravive announced the achievement of full enrollment in the registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer, PROC. The global, randomized, double-blind, placebo-controlled Phase 3 AXLerate-OC trial is evaluating efficacy and tolerability of 15 mg/kg batiraxcept in combination with weekly paclitaxel versus placebo in combination with weekly paclitaxel. The trial was planned to enroll approximately 350 patients with platinum resistant, high grade serous ovarian cancer who received 1-4 prior lines of therapy at approximately 165 sites in the U.S. and Europe. "Completing enrollment of this pivotal study brings us closer to the day when batiraxcept potentially is available to patients," said Scott Dove, Ph.D., Chief Operating Officer of Aravive. "Public reporting of topline data remains on track for mid-2023 and, if successful, are expected to support a Biologics License Application for PROC at the end of 2023. I would like to thank the patients enrolled in the trial, the clinical investigators, our CRO partners, and the Aravive team who worked tirelessly to advance the trial to this stage."

07:06 EST Enbridge renews normal course issuer bid - Enbridge announced that the Toronto Stock Exchange has approved the company's new normal course issuer bid to purchase, for cancellation, up to 27,938,163 of its outstanding common shares to an aggregate amount of up to $1.5B.

07:06 EST Fulcrum Therapeutics provides business update, upcoming milestones - "We are entering 2023 with a tremendous amount of momentum and expect it to be a productive year for our two clinical programs: FTX-6058 for SCD, and losmapimod for FSHD," said Robert Gould, Ph.D., Fulcrum's interim president and CEO. "FTX-6058 is a potential best-in-class oral HbF inducer candidate that could address critical gaps in the SCD treatment landscape. We are excited by the levels of HbF induction in our initial doses and look forward to further broadening our understanding of its effect at a higher dose. Meanwhile, the Phase 3 REACH trial with losmapimod, a potential first-to-market therapy in FSHD, is expected to complete enrollment in the second half of the year." Key Business Updates and Upcoming Milestones: FTX-6058: Received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of SCD in December 2022; Phase 1b data from Cohort 1 subjects in the 6 mg cohort showed up to 9.5% absolute HbF increases from baseline; data suggest no difference in response in subjects on and off background hydroxyurea; Improved biomarkers of hemolysis in evaluable patients dosed at 6 mg; In the Phase 1b trial, FTX-6058 appears to have dose dependent and clinically relevant increases in HbF; all subjects adherent to dosing regimen showed a response; Generally well tolerated with no drug-related treatment emergent serious adverse events and no discontinuations due to treatment emergent adverse events to date; Enrolling 12 mg dose cohort of the Phase 1b trial; Next data update planned during the fourth quarter of 2023. Losmapimod: Enrollment ongoing in the REACH Phase 3 pivotal trial at sites in the U.S., Canada, and Europe; Plan to complete enrollment in the second half of 2023.

07:05 EST EyePoint announces promotion of COO Duker to President - EyePoint Pharmaceuticals announced that Jay Duker, M.D., who has served as the company's Chief Operating Officer, COO, since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker will also oversee regulatory affairs. Prior to serving as Chief Operating Officer at EyePoint, Dr. Duker held earlier roles at EyePoint as Chief Strategic Scientific Officer on a part-time basis beginning in 2020, after having served as an independent member of EyePoint's Board of Directors since 2016.

07:04 EST Sterling Check announces acquisition of Socrates - Sterling Check announced that it has acquired Socrates. This acquisition expands Sterling's global presence into Latin America to serve the rapidly growing regional hiring needs of both multi-national and local clients. "This is an incredible opportunity to expand Sterling's presence into a region with rapidly increasing hiring demand across our clients, especially in financial services and technology," said Josh Peirez, CEO, Sterling. "The Socrates team has built a highly reliable operational model and suite of screening services, guided by their people-first, client-centric values that are a perfect fit with the Sterling culture." Socrates's expert management team will join the Sterling leadership team, building upon Sterling's proven model of bringing deep regional expertise, innovative localized solutions, and unrivaled client service to deliver growth in the region. The transaction was fully funded by cash on the balance sheet.

07:03 EST Tiziana Life Sciences announces IND filed for Phase 2 study of milciclib - Tiziana Life Sciences announced the Investigational New Drug, IND, application filing for milciclib in combination with gemcitabine for non-small cell lung cancer, NSCLC. "This Phase 2 IND filing, which was achieved with minimal additional resource deployment, enhances the asset value and Tiziana's optionality for milciclib," commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana. "Milciclib previously showed encouraging results in several cancer clinical studies - both as a monotherapy and in combination with gemcitabine. We believe that there could be an important role for a pan-CDK inhibitor in the oncologist's toolbox. At the same time, we are highly focused on advancing our leading CNS-focused programs with intranasal foralumab, which continues to generate encouraging data in our expanded access trial of secondary progressive multiple sclerosis."

07:02 EST Lannett updates on biosimilar insulin aspart and biosimilar insulin glargine - Lannett provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products. Lannett is developing both products with its strategic alliance partner, the HEC Group of companies, or HEC. The company said results from the study of Lannett/HEC biosimilar insulin aspart versus US NovoLog indicated the products were highly comparable when animals were dosed with equal quantities of the drugs via subcutaneous route. Data from the study will be submitted to the FDA as part of the company's request, expected in the first half of calendar 2023, for a Biosimilar Biological Product Development, or BPD, Type II meeting. The company also said that analysis of the pivotal trial results for its biosimilar insulin glargine continues, though it now anticipates top-line data to be available by the end of February 2023.

06:58 EST Geron reports 'positive' results from IMerge Phase 3 trial of imetelstat - Geron announced positive top-line results from its IMerge Phase 3 clinical trial evaluating the company's first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes patients who are relapsed, refractory or ineligible for erythropoiesis stimulating agents. The trial met its primary efficacy endpoint of 8-week TI and a key secondary endpoint of 24-week TI, demonstrating highly statistically significant and clinically meaningful benefit of imetelstat versus placebo with no new safety signals and safety results consistent with prior imetelstat clinical trials. In light of the positive top-line results from IMerge Phase 3, combined with data from earlier clinical trials, the company plans to submit an NDA in the U.S. in mid-2023 and a Marketing Authorization Application in the EU in the second half of 2023. With Fast Track designation for imetelstat from the U.S. FDA for the treatment of adult patients with transfusion dependent anemia due to Low or Intermediate-1 risk MDS that is not associated with del(5q) who are refractory or resistant to an ESA, a request for rolling submission of the NDA was submitted and has been granted. Geron also plans to present additional data from IMerge Phase 3 at medical meetings later this year, including data relating to potential correlations of decreases in mutation burden and abnormal cytogenetic clones with clinical responses, patient reported outcomes, hTERT and telomerase activity biomarker data and continued follow-up of durability of transfusion independence, that may be indicative of the potential for disease modification with imetelstat. Geron is preparing for an anticipated commercial launch of imetelstat in lower risk MDS in the first half of 2024 in the U.S. and by the end of 2024 in the EU, assuming regulatory approvals are granted.

06:52 EST Nuscale Power, RoPower sign contract for development of SMR plant in Romania - NuScale Power and Romania's RoPower Nuclear S.A., owned in equal shares by S.N. Nuclearelectrica S.A. and Nova Power & Gas S.A., announced that a contract for Front-End Engineering and Design work was signed between parties on December 28, 2022, marking a significant step toward the deployment of a NuScale VOYGR small modular reactor power plant in Romania. Phase 1 of the FEED work awarded to NuScale will define the major site and specific inputs for a VOYGR-6 SMR power plant to be deployed at the Doicesti Power Station site in Romania. The eight-month project includes the issuance of subcontracts to perform the environmental impact assessment and subsurface geotechnical investigation, the evaluation of site and site-specific requirements for NuScale's standard plant design, and the development of a project-specific cost estimate.

06:36 EST Salesforce announces restructuring, 10% workforce reduction - In a regulatory filing, the company stated, "On January 4, 2023, Salesforce announced a restructuring plan intended to reduce operating costs, improve operating margins, and continue advancing the company's ongoing commitment to profitable growth. The Plan includes a reduction of the company's current workforce by approximately 10 percent and select real estate exits and office space reductions within certain markets. Decisions regarding the elimination of positions are subject to local law and consultation requirements in certain countries, as well as the company's business needs. The company estimates that it will incur approximately $1.4 billion to $2.1 billion in charges in connection with the Plan, of which approximately $800 million to $1.0 billion is expected to be incurred in the fourth quarter of fiscal 2023. These charges consist primarily of $1.0 billion to $1.4 billion in charges related to employee transition, severance payments, employee benefits, and share-based compensation; and $450 million to $650 million in exit charges associated with the office space reductions. Of the aggregate amount of charges that the Company estimates it will incur in connection with the Plan, the company expects that approximately $1.2 billion to $1.7 billion will be in future cash expenditures.The actions associated with the employee restructuring under the Plan are expected to be substantially complete by the end of the company's fiscal 2024, subject to local law and consultation requirements. The actions associated with the real estate restructuring under the Plan are expected to be fully complete in fiscal 2026. The estimates of the charges and expenditures that the company expects to incur in connection with the Plan, and the timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual amounts may differ materially from estimates. In addition, the company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the Plan."

06:31 EST G1 Therapeutics provides update on PRESERVE 3 trial - G1 Therapeutics provided an initial update on PRESERVE 3, an ongoing Phase 2, randomized, open-label study of first-line platinum-based chemotherapy and maintenance therapy with the immune checkpoint inhibitor, avelumab, administered alone, or in combination with trilaciclib, in patients with untreated, locally advanced or metastatic urothelial carcinoma. Additional safety and efficacy data, including the primary endpoint of progression free survival, are anticipated in the middle of 2023. Initial Phase 2 Results: The confirmed objective response rate per RECIST v1.1 was comparable between arms; ORR was 40.0% and 46.7% among evaluable patients in the trilaciclib and control arms, respectively. Longer-term follow-up is required to characterize additional anti-tumor endpoints including median duration of confirmed objective response and PFS, which is the primary endpoint of the study. Safety is reviewed by the data monitoring committee on an ongoing basis, and it has recommended that the study continue as planned. Though early, the safety and tolerability profile of trilaciclib administered prior to chemotherapy is generally consistent with that expected in patients treated with gemcitabine plus cisplatin/carboplatin and avelumab maintenance for previously untreated advanced or metastatic urothelial carcinoma.

06:07 EST Roivant Sciences announces 'positive' results from Phase 2b study of RVT-3101 - Roivant Sciences announced positive results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101 (previously PF-06480605), a once monthly subcutaneously administered anti-TL1A antibody which demonstrated statistically significant and clinically meaningful efficacy results at each dose tested. RVT-3101 was well tolerated and showed a favorable safety profile. RVT-3101 will progress into registrational studies as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis. TUSCANY-2 is a large, global, randomized, double-blind, placebo-controlled dose-ranging Phase 2b study to investigate the efficacy, safety, and pharmacokinetics of RVT-3101 in 245 adult participants with moderate to severe ulcerative colitis. TUSCANY-2 is a 52-week study, with a 12-week induction period comparing different doses of RVT-3101 against placebo, and a 40-week chronic therapy period during which all subjects receive RVT-3101. The chronic therapy period is still ongoing with data expected in 1H 2023. During the induction period, patients were treated monthly with subcutaneous RVT-3101 at 50 mg, 150 mg, and 450 mg without a loading dose required. RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested. These results demonstrated best-in-indication potential for RVT-3101 across the full population of moderate to severe ulcerative colitis patients, with enhanced efficacy in patients who were positive for a prospectively defined biomarker regardless of prior biologic experience. RVT-3101 has the potential to be both a highly efficacious first- or second-line treatment and a preferred precision medicine in the approximately 60% of patients who are biomarker positive. Roivant expects to report data from the chronic therapy period of TUSCANY-2 in 1H 2023.

06:04 EST Genius Sports, SoftConstruct settle legal dispute - Genius Sports and SoftConstruct have agreed a settlement to resolve their legal dispute. As part of this settlement SoftConstruct have agreed to purchase a multi-year license to supply Genius' market-leading data via its BetConstruct and FeedConstruct channels, with such license acknowledging Genius's ownership of database rights. "Genius invests significant time, resource, and expertise in creating and developing market-leading technology and databases to collect and supply sports data products across the industry," says Jack Davison, Genius Sports' Chief Commercial Officer. "We are delighted that the SoftContruct team have recognized this value and we look forward to working in partnership with them as we move forward." "This deal enables us to service our customers with the best data," says Armand Pinarbasi SoftConstruct's CEO. "We can now look forward to a mutually beneficial relationship in the years to come."

06:03 EST ReneSola to repurchase from ReneSola Singapore 3M ADSs for $13.2M - ReneSola announced that the company has entered into a securities repurchase agreement with ReneSola Singapore, pursuant to which, among other things, the company will repurchase from ReneSola Singapore 3M ADSs at a price of $4.40 per ADS, totaling $13.2M through a privately negotiated transaction. In addition, Shah Capital will purchase the remaining 2.05M ADSs owned by ReneSola Singapore at a price of $4.40 per ADS, totaling $9.02M through a privately negotiated transaction. The purchase price represents 25% discount to SOL's net asset value as of September 30, 2022. The closing of the share repurchase is expected to occur within three business days from January 4, subject to standard closing conditions. After the completion of the two transactions, ReneSola Power's primary shareholders will be all domiciled outside of China.

06:01 EST Applied Therapeutics partners with Advanz Pharma to commercialize AT-007 - Applied Therapeutics announced a partnership with Advanz Pharma, a pharmaceutical company with a strategic focus on commercialization of specialty, hospital, and rare disease medicines, for commercialization of AT-007 (govorestat) in Europe. Under the terms of the agreement: Applied Therapeutics will receive certain near-term development milestones upon clinical trial completion and marketing authorization in Europe as well as commercial sales milestones, which in the aggregate amount to over EUR 130 million, including EUR 10 million upfront due upon signing. Applied Therapeutics will receive royalties on any future net sales of AT-007 in Europe of 20%. Applied Therapeutics will continue to be responsible for the development, manufacturing and supply of AT-007, and Advanz Pharma will be responsible for packaging, distribution and commercialization in Europe. Advanz Pharma receives exclusive commercial rights in the European Economic Area, Switzerland, and the UK for AT-007 in Galactosemia and SORD Deficiency, with certain rights to future indications for AT-007 in Europe.

05:51 EST Amazon.com secures into $8B term loan - In a regulatory filing on Tuesday, Amazon said that it, Toronto Dominion, as administrative agent, and the other lenders party thereto entered into a credit agreement. The Term Loan Agreement provides the company with an unsecured $8B term loan that will mature in 364 days, but may be extended for an additional period of 364 days. The initial interest rate applicable to the Term Loan is the Secured Overnight Financing Rate plus 0.75%. If the company exercises its option to extend the Term Loan's maturity for an additional 364 days, the interest rate spread will increase from 0.75% to 1.05%. Upon funding, proceeds of the Term Loan will be used for general corporate purposes, Amazon said in the filing.

05:11 EST Ambarella, Kodiak Robotics announce integration partnership for CV2AQ AI SoC - Kodiak Robotics announced a partnership with Ambarella to integrate Ambarella's CV2AQ AI perception system-on-chip, or SoC, into its self-driving trucks for all camera data processing. To kick off the partnership publicly, Kodiak will exhibit one of its self-driving trucks at Ambarella's demo event in Las Vegas during the 2023 Consumer Electronics Show, or CES.